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Current treatment options for malignant brain tumors not only frequently fail to 
cure the disease due to local recurrence, but also may severely compromise quality of 
remaining life even when tumor mass is reduced in large part because they interfere with 
mechanisms of neuroplasticity and function of bystander tissue. The aims of this 
dissertation are to: (a) assess neurological impairments associated with rapid focal 
cortical tissue displacement; (b) evaluate the specific impact of conventional and novel 
treatments on neurorestoration while controlling tissue compression without the confound 
of related events linked to tumor physiology; (c) identify the behavioral change pattern 
 viii
during brain tumor progression and investigate the stealth nature of brain tumors; (d) 
demonstrate how anti-cancer treatments affect brain function especially when 
administered in the silent stages of brain tumors; and (e) develop treatment strategies that 
might improve therapeutic effectiveness and brain function.  
We adopted a new focal mass compression model providing rapid displacement 
of tissue in the underlying sensorimotor cortex, as well as the traditional rat and mouse 
glioma xenograft models that exhibit prominent tumor growth and invasion, given the 
varied aims and contexts of our different studies. Various conventional and novel brain 
tumor treatments were employed in this dissertation, including local and systemic 
chemotherapy, antiangiogenic agents, photodynamic therapy, and a glutamate antagonist. 
A neurorestorative therapy with atorvastatin was evaluated in its effects on functional 
recovery after photodynamic therapy.  
Functional outcomes were measured with an array of behavioral tests, which are 
sensitive to mild focal insults to the sensorimotor cortex and can detect recovery of 
function. Histopathological assessments consisted of Nissl staining, hematoxylin-and-
eosin (H&E) staining, and immunohistochemistry, depending on varied purposes, used in 
conjunction with a computer imaging analysis system.  
In clinical trials, functional outcome is as critical to gauging the success of a 
treatment as is patient survival time. Both preclinical screening of anti-cancer 
interventions for the ability to shrink tumors effectively with minimal disturbance of 
neuroplasticity and developing combination therapy with neurorestorative regimens 
following neurotoxic cancer treatments should allow for optimal promotion of plastic 
mechanisms in the remaining normal brain tissue. 
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Chapter 1:  Introduction 
1.1 EPIDEMIOLOGY, SYMPTOMS AND TREATMENT OF BRAIN TUMORS 
The incidence rate of brain tumors is 14 per 100,000 with the five-year survival 
rate only 25.6% (central brain tumor registry of the United States, CBTRUS, 1995-1999 
Data). Approximately 17,000 people develop new cases of primary brain tumors each 
year in the United States (Landis et al., 1998). About 60% of primary brain tumors are 
gliomas and the majority of these are clinically aggressive and high grade (Ries et al., 
1991). Central nervous system (CNS) neoplasm is the most common type of all 
childhood solid tumors and the No. 2 leading cause of cancer deaths in children (Wingo 
et al., 1995). Despite the routine therapy—resection surgery, radiation and chemotherapy, 
the prognosis is generally grim with 24.6 average life years lost for CNS cancers 
［surveillance epidemiology and end results (SEER) ］. 
Brain tumors are distinguished from other tumors in that every brain area has an 
associated function, and the tumors arise in the skull with little room for expansion. Brain 
tumors carry high rates of mortality and morbidity. Symptoms of brain tumors are 
produced by the tumor mass primarily, and also by the surrounding edema, the 
infiltration and destruction of normal brain tissue (Soo et al., 1995). The nonspecific 
symptoms of brain tumors, due to increased intracerebral pressure (ICP), are headache, 
nausea and vomiting. The specific signs and symptoms, depending on the tumor location, 
include seizures, aphasia, visual deficits, hearing loss, one-sided muscle weakness 
(hemiparesis), and changes in personality, concentration and memory (DeAngelis et al., 
2004). In the early stage of many types of brain tumors, the tumor grows so slowly and 
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the symptoms appear so gradually that they may be ignored for a long period, which 
results in a delayed diagnosis.  
Surgery is generally the first step and the most effective treatment for both 
malignant and non-malignant brain tumors to reduce tumor size as well as brain pressure. 
Radiation therapy plays a central role in the management of malignant tumors and 
chemotherapy is important in prolonging the survival in some but not all types of brain 
tumors. Although most primary brain tumors rarely metastasize, the regional infiltration 
into the surrounding normal tissue during tumor progression leads to badly demarcated 
borders and underlies their great propensity for recurrence (Mikkelsen and Edvardsen, 
1996). Malignant gliomas are highly invasive, characterized by high incidence of 
recurrence and poor prognosis (Burger and Kleihues, 1989; Nicholas et al., 1997; 
Kleihues et al., 2002). Aggressive brain tumor treatments, such as extensive surgical 
resection, high dose radiation and local chemotherapy, tend to enhance tumor destruction 
and delay tumor recurrence. However, this goal is built upon damage to adjacent normal 
tissue, and thus not easily attained. Therefore, novel therapeutic strategies aimed at 
improving the efficacy/toxicity ratio are desperately needed. New compounds, that 
demonstrate selective tumor localization and/or can increase the sensitivity of tumor cells 
to radiotherapy, chemotherapy, and photodynamic therapy (Sessler and Miller, 2000; 
Magda et al., 2001; Naumovski et al., 2005; Wei et al., 2005b; Naumovski et al., 2006; 
Wang et al., 2007b), represent the future of cancer treatment.  
1.2 DILEMMAS IN TREATING BRAIN TUMORS 
The ultimate goal in tumor therapy is to cure the disease and save life. To fulfill 
the goal, a combination of treatment modalities is needed, including “killing paradigms”, 
such as surgery, radiation, chemotherapy, aimed at maximal debulking of tumor burden 
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and destruction of tumor cells in the circulatory system, as well as “regulatory 
paradigms”, such as anti-invasive and anti-angiogenic treatments, aimed at controlling 
tumor growth and spread (Mikkelsen, 1998). For brain tumors, the “killing paradigms” 
can directly damage the surrounding normal brain tissue, due to their toxicity and lack of 
selectivity. The “regulatory paradigms” may not directly damage normal brain tissue, but 
they may harm the neuroplastic mechanisms which are important in functional recovery. 
Inhibition of vascular endothelial growth factor (VEGF) suppresses the growth of 
gliomas (Kim et al., 1993; Cheng et al., 1996); however, it also impedes revascularization 
and neural repair after brain injury (Krum and Khaibullina, 2003). Inhibition of basic 
fibroblast growth factor (FGF-2) impedes glioma growth (Stan et al., 1995); however, it 
also retards functional recovery from motor cortex injury (Rowntree and Kolb, 1997). 
Low-dose radiation attenuates neurogenesis and exacerbates ischemia-induced functional 
deficits (Raber et al., 2004). Many treatments that can shrink brain tumors may not 
increase survival meaningfully, and even if they increase survival, they may not 
necessarily improve function, at least not optimally, because of adverse effects on 
restorative mechanisms. Radiation and chemotherapy are widely blamed for their 
neurological complications (Vigliani et al., 1999; Plotkin and Wen, 2003; Aarsen et al., 
2006). Deterioration in neurological function is accompanied by significant deterioration 
in global quality of life in patients with high-grade glioma (Osoba et al., 1997). The need 
for functional improvement and prevention of further neurological decline is well 
appreciated but difficult to investigate systematically because the functional benefit of 
treatments that shrink tumors might be offset if treatments compromise processes critical 
to recovery and maintenance of function.  
Current supportive treatment primarily includes anticonvulsants and 
corticosteroids, focusing on relieving symptoms (DeAngelis et al., 2004). However, no 
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neurorehabilitative strategy is clinically available to protect from treatment-related 
toxicity and improve long-term neurological function. Ramipril, an inhibitor of 
angiotensin-converting enzyme (ACE), ameliorates radiation-induced brain damage in a 
rat optic neuropathy model (Kim et al., 2004). A thrombin inhibitor was used in a rat 
glioma model to reduce tumor size with functional benefit (Hua et al., 2005a; Hua et al., 
2005b). A preliminary, retrospective investigation in a sample of patients with primary 
malignant brain tumors showed the effectiveness of postacute brain injury rehabilitation 
methods, originally developed for traumatic brain injury survivors, in ameliorating 
neurobehavioral deficits due to the tumor, surgical resection, and subsequent radiation 
and chemotherapy (Sherer et al., 1997). 
To a limited extent, the brain repairs itself after damage. Neurogenesis, 
angiogenesis, upregulation of growth factors and inhibition of spontaneous apoptosis play 
important roles in the recovery and restoration after stroke and other brain injuries 
(Gomez-Pinilla et al., 1992; Cramer and Chopp, 2000; Chao et al., 2002; Keyvani and 
Schallert, 2002; Mattson et al., 2002; Parent et al., 2002). A brain tumor, acting as a 
lesion, can trigger reactive neuroplastic responses that make the brain adapt to the tumor 
insult gradually (Duntsch et al., 2005; Glass et al., 2005; Bexell et al., 2007; Yang et al., 
2007b). However, many of the developmental and neuroplastic mechanisms also may be 
what brain tumors rely on to support growth, differentiation, invasion and metastasis 
(Eberhart et al., 2001; Singh et al., 2004; Arrieta et al., 2005; Kaur et al., 2005; Rege et 
al., 2005). Gliomas are angiogenesis-dependent (Plate and Risau, 1995; Kargiotis et al., 
2006). VEGF secreted by glioma cells plays a prime role in the induction of tumor 
angiogenesis (Plate et al., 1992; Plate et al., 1993; Plate et al., 1994). FGF-2 produced by 
some types of gliomas is related to angiogenesis and tumorigenicity (Stan et al., 1995; 
Segal et al., 1997; Ke et al., 2000; Auguste et al., 2001). Again, one of the dilemmas 
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confronting brain tumor management is that treatment regimens targeting tumor 
promotion pathways may depress neuroplasticity and functional recovery. To summarize, 
neutralization of endogenous VEGF causes decreases in angiogenic activity and astroglial 
proliferation, resulting in impediment to neural repair following stab wound brain injury 
(Krum and Khaibullina, 2003). Blockade of FGF-2 with neutralizing antibodies retards 
functional recovery from suction lesions of the motor cortex (Rowntree and Kolb, 1997). 
On the other side, treatments that can protect and benefit injured neuronal tissue may also 
protect and benefit tumor tissue. Fluid derived from wound injury was shown to 
accelerate growth of C6 glioma in spheroid culture, suggesting the stimulatory effect of 
injury on tumor progression (Abramovitch et al., 1999).  
However, brain repair and tumor suppression may not always be contradictory 
and they can possibly be monitored in the same way. Malignant glioma cells attract 
endogenous precursor cells as a reparative mechanism and the presence of precursor cells 
is antitumorigenic (Duntsch et al., 2005; Glass et al., 2005; Bexell et al., 2007). Increased 
neuronal differentiation and synaptogenesis are associated with decreased aggressiveness 
in retinoblastoma (Johnson et al., 2007). Neurotrophins [Nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), and Neurotrophin 3 (NT-3)] are essential 
mediators of proliferation, differentiation, and survival of cells in the normal brain 
(Ibanez et al., 1995). BDNF is widely established as a major trophic factor in normal and 
injured brain function (Keyvani and Schallert, 2002; Vaynman et al., 2004; Kim et al., 
2005; Kleim et al., 2006). Human origin gliomas generate neurotrophins with BDNF 
being the most abundantly expressed, and extrinsic neurotrophins failed to stimulate 
mitosis of the glioma cultures (Hamel et al., 1993). There is evidence that neurotrophin 
signaling is involved in the process of apoptosis and neuronal differentiation in 
medulloblastomas (Chou et al., 1997; Eberhart et al., 2001). Whereas in normal blood 
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vessel Ang-1 expression exceeds Ang-2 expression, the opposite is true in tumor blood 
vessels (Stratmann et al., 1998; Tse et al., 2003). Block of the stabilizing effect of Ang1 
on both preexisting and newly formed blood vessels by Ang2 cooperates with VEGF to 
induce tumor blood vessel growth (Stratmann et al., 1998; Holash et al., 1999; Zagzag et 
al., 1999; Audero et al., 2001; Ding et al., 2001; Papetti and Herman, 2002; Tse et al., 
2003). Therefore, normalization of the expression pattern of Ang-1, Ang-2 and their 
endothelial cell receptor Tie2 may normalize the abnormal structure and function of 
tumor vasculature to make it more efficient for oxygen and anti-cancer drug delivery 
(Jain, 2005). Interestingly, in addition to reducing vascular permeability and enhancing 
vascular stabilization and maturation (Suri et al., 1996; Suri et al., 1998), Ang1 can 
trigger the migration of immature neurons to the site of brain damage and promote 
functional recovery after stroke (Ohab et al., 2006), thus linking the two processes of 
neurogenesis and angiogenesis together.  
1.3 AIMS OF THE DISSERTATION RESEARCH 
The main challenge for modern brain cancer research is to design novel 
interventions or improve the existing therapy to reduce undesirable neurological side 
effects while maintaining anti-cancer efficacy, as well as to develop treatments that can 
provide neuroprotection during cancer therapy or promote neurorestoration afterwards. In 
clinical trials, functional outcome is a major target, but seems to be neglected in 
translational brain tumor research. This might be due to the assumption that it should be 
primary for a treatment to avert a patient’s death, or that reduction of tumor size may 
result in functional improvement in parallel. However, it may also be that there has been 
a lack of suitable experimental approaches to assess the adverse effects of anti-cancer 
treatments on functional outcomes. Unfortunately, this void places a serious limitation on 
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the ability to weigh the risks and benefits of new therapies and to develop strategies to 
rehabilitate damaged function.  
To summarize, limitations of contemporary brain tumor research are that: 1) 
Preclinically promising anti-cancer treatments can cause worsening of neurological 
symptoms in clinical trials; 2) Functional measurements are rarely used in preclinical 
cancer research; 3) Injury and neuroplastic mechanisms induced by brain tumor 
progression are not clear; 4) There is a distinct lack of research on developing treatments 
that can provide neuroprotection during cancer therapy or promote neurorestoration 
afterwards. 
Fig. 1.1 shows the overview of the whole dissertation. My dissertation research 
was aimed at developing animal models to facilitate preclinical screening for anti-cancer 
drugs with minimum neurotoxicity and reduced harm to neuroplasticity and to assist the 
investigation of rehabilitative strategies after aggressive anti-cancer therapy. 
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Figure 1.1:  Overview of the dissertation. 
To fulfill this aim, the following related experiments were conducted: (a) 
development of a mass compression model with epidural implantation of a hemisphere-
shaped bead over the sensorimotor cortex and assessment of the behavioral deficits 
following varied location, magnitude and duration of the focal compression (Chapter 2); 
(b) evaluation of the impacts of two examples of novel brain tumor treatments - an 
NMDA glutamate antagonist MK801 (Chapter 3) and local fluorouracil chemotherapy 
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(Chapter 4) on neurorestoration using the mass compression model; (c) measurement of 
the functional deficits in orthotopic rodent glioma models and investigation of the tumor-
induced brain plasticity mechanisms (Chapter 5); (d) evaluation of the functional 
outcomes after anti-cancer treatments, including antiangiogenic treatment (Chapter 6) and 
systemic chemotherapy (Chapter 7) as examples, administered in the dormant stages of 
brain tumors; and (e) measurement of the functional responses after photodynamic 
therapy in normal brain and evaluation of the functional outcomes of a novel combination 
therapy with photodynamic therapy and a neurorestorative agent atorvastatin (Chapter 8). 
This dissertation is composed of a wide variety of experiments conducted on 
various models, including a focal brain compression model and a tumor cell implantation 
model. The dissertation has a seemingly loose structure, but a strict internal logic. First, 
in many cases, reduction of tumor may result in functional improvement in parallel, and 
the effects of mass reduction may mask the adverse effects of the treatment on the 
integrity of brain function. Therefore, a model that can hold tumor size constant 
independent of treatment may help assess the potential detrimental effects of tumor 
growth inhibitors on brain plasticity more directly. We then adopted an epiducal bead 
implantation model which was first developed by Chen et al. in 2003 (Chen et al., 
2003b). The hemisphere-shaped plastic bead is like a mechanical tumor, which can 
induce significant focal brain compression, and can be either left remained or removed 
when needed. However, before this model can be used to screen for anti-cancer drugs 
with reduced adverse effects on brain function, we need to characterize the behavioral 
change pattern of this focal brain compression model. Because location and size are two 
major factors that determine clinical signs and symptoms of brain tumors and surgical 
resection is the most important treatment for brain tumors, we then investigated how 
location, duration and magnitude of the focal compression might affect the behavioral 
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changes, with two factors fixed and the other one changed once a time. Each time, we 
changed one single factor, and compared the behavioral responses, when the bead was 
implanted into varied locations over the sensorimotor cortex (SMC), when the bead was 
removed at different times, and when different sizes of beads were implanted, 
respectively. Finally, we found that the model of 2-mm-thick bead remained implanted 
over the middle SMC is suitable to investigate the potential adverse effects of anti-cancer 
treatments on functional recovery, because it can reliably induce transient, mild, but 
significant behavioral deficits in all of the four behavioral tests that we used, including 
forelimb asymmetry, somatosensory asymmetry, and placing tests. We then used this 
bead compression model to assess the behavioral responses after treatment with 
glutamate antagonist MK801 and 5FU local chemotherapy, respectively, as two examples 
to show “proof of principle”, because they are both novel treatments that can reduce 
glioma growth according to literature (Menei et al., 1996; Lemaire et al., 2001; Rzeski et 
al., 2001; Takano et al., 2001; Ishiuchi et al., 2002; Fournier et al., 2003; Menei et al., 
2004), and may possibly interfere with functional recovery after focal brain compression.  
Second, how rats bearing gliomas grown in the SMC and the underlying striatum 
behave in our sensorimotor tests is unknown, and warrants investigation, because the 
glioma implantation model is to date the closest model to mimic clinical tumor 
characteristics in human patients. Therefore, we implanted 9L glioma cells into the SMC 
of Fischer rats and measured their behaviors repeatedly until they started to die. We 
found that the average behavioral performance was not significant until very late stage of 
tumor growth, although some of the animals showed substantial functional impairment 
earlier. Histological analyses indicated that there were some variabilities in tumor growth 
rate. Therefore, a closer case-by-case tumor volume-behavior correlation needs to be 
evaluated to clarify how tumor progression affects rats’ behavior. Magnetic resonance 
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imaging (MRI) was then used to monitor tumor volume right after the behavioral testing. 
Regression analyses were performed to correlate the behavioral test score with the 
corresponding tumor volume. To investigate whether a brain tumor is like a lesion which 
can induce neuroplasticity, immunohistochemistry was performed to assess the 
expression levels of multiple markers for neurons, astrocytes, endothelial cells, and 
synaptogenesis in the peri-tumoral area. From testing the glioma-bearing animals, we 
found a dormant period of tumor growth, in which no significant behavioral deficits were 
exhibited. We then used this glioma implantation model to investigate whether certain 
cancer therapies can cause worsening of functional deficits in the dormant stage of tumor 
growth. Antiangiogenic therapy is a relatively new form of cancer treatment using 
angiogenesis inhibitors that specifically halt new blood vessel growth and starve a tumor 
by cutting off its blood supply. We had two antiangiogenic agents available in the lab, 
which are antibodies against vascular endothelial growth factor receptor (VEGFR) -1 and 
2, respectively. It has recently been shown in the literature that combination of the two 
antibodies targeting both VEGFR-1 and VEGFR-2 is more effective than either single 
antibody to treat cancers (Lyden et al., 2001). However, the two antibodies available in 
the lab are both designed targeting mouse antigens. We then employed a nude mouse 
intracranial model using the U87 malignant glioma cell line to investigate the behavioral 
response after systemic administration of antiangiogenic therapy during the dormant 
period of tumor growth. BCNU is a classic chemotherapy drug which has been the 
mainstay of management of malignant glioma in clinic for decades. We used the rat 9L 
glioma model to investigate the behavioral response after systemic administration of 
BCNU during the dormant period of tumor growth. We found that both the 
antiangiogenic agents and BCNU retarded or inhibited the onset of significant behavioral 
deficits without affecting brain function adversely in the dormant stages of tumor 
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development. However, the behavioral performances with or without anti-cancer therapy 
were compared under the conditions of different tumor sizes, due to the tumor reduction 
effect of the anti-cancer therapies. Therefore, this tumor implantation model is not 
suitable to detect the potential adverse effects of anti-cancer therapies on neuroplasticity. 
These experiments, in fact, prove the necessity of using a controlled-rate non-tumor 
compression/decompression model to detect the potential adverse effects of anti-cancer 
therapies on neuroplasticity.  
Third, not only brain tumors themselves can cause damage, conventional cancer 
treatment approaches, such as surgical tumor resection, radiotherapy and chemotherapy, 
can also cause neurological impairment. Usually in the clinic, surgical resection is 
performed as soon as a brain tumor is diagnosed if allowed. Radiation and chemotherapy 
may be used in conjunction with surgery. To mimic the aggressive local tumor killing 
procedure, and to simplify the model, we used a photodynamic therapy on the normal 
brain to show the principle of direct brain tissue damage by a cancer therapy. A model 
with severe and stable behavioral deficits is suitable to investigate a treatment’s 
functional restorative effects. We measured the behavioral deficits associated with high-
dose photodynamic therapy. We then investigated whether a neurorestorative treatment 
can promote the functional recovery after photodynamic therapy. Atorvastatin was our 
first attempt, because atorvastatin has shown significant neurorestorative effects in 
models of stroke, intracerebral hemorrhage, and traumatic brain injury (Chen et al., 
2003a; Lu et al., 2004c; Lu et al., 2004b; Lu et al., 2004d; Lu et al., 2004a; Seyfried et 
al., 2004; Chen et al., 2005).  
To summarize, the goal of this set of experiments was to start to fill a critical 
behavioral void in the early phases of translational brain tumor research. A longer term 
hope is for an improved collaboration among scientists in the areas of behavioral 
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neuroscience, experimental and clinical neuro-oncology, neurosurgery and neurology to 
find better ways to help patients have maximum functioning and quality of life. 
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Chapter 2:  Mass-induced Brain Tissue Displacement and Behavioral 
Impairment  
This work is published in Journal of Neurotrauma in 2006 (Yang et al., 2006c). 
2.1 ABSTRACT 
This study was focused on a preclinical model of brain compression injury which 
has relevance to the pathological condition of a brain tumor. Behavioral impairment as a 
result of rapid-onset small mass, and the factors involved in lesion formation and 
neuroplasticity were investigated. An epidural bead implantation method was adopted. 
Two sizes (1.5 mm and 2.0 mm thick) of hemisphere-shaped beads were used. The beads 
were implanted into various locations over the sensorimotor cortex (SMC- anterior, 
middle and posterior). The effects of early vs. delayed bead removal were examined to 
model clinical neurosurgical or other treatment procedures. Forelimb and hind-limb 
behavioral deficits and recovery were observed and histological changes were quantified 
to determine brain reaction to focal compression. Our results showed that the behavioral 
deficits of compression were influenced by the location, timing of compression release, 
and magnitude of compression. Even persistent compression by the thicker bead (2.0 
mm) caused only minor behavioral deficits, followed by fast recovery within a week in 
most animals, suggesting a mild lesion pattern for this model. Brain tissue was 
compressed into a deformed shape under pressure with slight tissue damage, evidenced 
by pathological evaluation on hematoxylin and eosin (H&E)- and terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)- stained sections. 
Detectable but not severe behavioral dysfunction exhibited by this model makes it 
particularly suitable for direct assessment of adverse effects of interventions on 
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neuroplasticity after brain compression injury. This model may permit development of 
treatment strategies to alleviate brain mass effects, without disrupting neuroplasticity. 
2.2 INTRODUCTION 
An additional space-occupying mass within the closed cavity of the skull on the 
normal brain (mass effect), either from brain trauma, tumor, intracranial hemorrhage, or 
infection, can block the circulation system for the cerebrospinal fluid, resulting in 
surrounding brain edema and an even larger mass is formed, which induces compression 
or displacement of brain tissue. Chen et al. first developed a novel focal compression 
model with epidural implantation of a plastic bead over the sensorimotor cortex (SMC), 
and investigated the morphological changes of the surrounding brain tissue (Chen et al., 
2003b). Although they reported that no obvious behavioral effects could be detected, it 
seemed reasonable that if sensitive enough tests were applied, mild deficits might be 
found in this model, which would enhance its value as a preclinical method to develop 
single or multi-target interventions that can reduce mass while promoting restorative 
events that contribute to “quality of life”. This study was focused on the examination of 
behavioral changes in the focal compression model and the neuroplasticity associated 
with the mass lesion localized in the SMC, using sensitive tests that can detect injury to 
this region, recovery of function and small variations in trauma extent. Behavioral 
deficits depend on which regions of the SMC are injured (Barth et al., 1990b; Baskin et 
al., 2003). This study observed the location-dependent behavioral effects of the 
compression injury. Furthermore, how different magnitudes of compression affect 
behavioral deficits without causing severe brain tissue damage was also investigated. In 
the clinic, surgical removal of the mass is often executed to reduce intracerebral pressure 
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in patients suffering from brain compression. Therefore, this study determined how 
different time points for compression release influence functional recovery.  
Quality of life after treatment for mass-related insults has not been adequately 
modeled, particularly functional outcome associated with brain integrity. Without 
controlling for mass effects specifically, it cannot be determined whether the treatment is 
maximally benign with respect to surviving brain tissue because the extremely beneficial 
effects of mass reduction would severely mask any adverse effects of the treatment on 
brain function. Moreover, because tumors can initiate cascades of pathological and non-
pathological events that are independent of mass per se, a model that does not initiate 
these cascades may allow one to investigate behavior-related mass effects independently 
and thus may be additionally useful.  
2.3 MATERIALS AND METHODS 
2.3.1 Subjects 
A total of 71 male Sprague Dawley rats (250-350 g) were used. They were housed 
in pairs in Plexiglas tub cages and were maintained on a 12:12 h light/dark cycle. Prior to 
the experiment they were tamed by gentle handling, and food and water were available ad 
libitum. 
2.3.2 Materials 
Two different sizes of hemispherical plastic beads with different thicknesses were 
used for focal compression surgeries. One is 4.8 mm in diameter and 1.5 mm in 
thickness, and the other is 4.8 mm in diameter and 2.0 mm in thickness. A small dent was 
drilled in the center of the flat surface for the convenience of orientation and removal. 
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2.3.3 Experimental model 
Rats were anesthetized with i.p. injections of Ketamine (90 mg/kg) and Xylazine 
(10 mg/kg). The epidural bead implantation surgery was performed as described by Chen 
et al. (2003). Briefly, each animal was secured to the stereotaxic apparatus (Kopf), the 
scalp was incised and an elliptical hole with 5.8 mm in long diameter and 3.8 mm in short 
diameter was drilled in the skull over the SMC. The plastic bead, with the flat surface 
facing upward, was slipped obliquely into the hole very slowly and carefully to avoid 
damage to the dura. After the bead was placed completely under the skull, it was pulled 
back along the short axis of the hole and fixed well into the epidural space. The bead can 
be inserted and fixed because the diameter of the bead is shorter than the long diameter of 
the skull hole but longer than the short diameter of the skull hole. The bead was moved 
gently using the dent and a needle until the center of the bead was located on the required 
coordinates. 
To compare the mechanical compression effects at different locations of the SMC, 
a plastic bead with 1.5 mm thickness was used, and the rats were divided into 3 groups. 
Group 1 (anterior group, n=6) underwent bead implantation with the compression center 
~2 mm rostral to the bregma and 2.5 mm lateral to the midline; Group 2 (middle group, 
n=10) was given bead implantation with the compression center 0.7 mm rostral to the 
bregma and 2.5 mm lateral to the midline; Group 3 (posterior group, n=6) received bead 
implantation with the compression center ~2 mm caudal to the bregma and 2.5 mm 
lateral to the midline.  
To detect the compression effects alone and to exclude the influence of the 
surgical procedure of skull removal on the behavioral results, Group 4 (control group, 
n=9) was designed to be compared with the group subjected to 1.5-mm-thick bead 
implantation over the middle SMC. The control group received only skull removal within 
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the same area as the middle group described above, but did not undergo bead 
implantation. 
To determine the effects of magnitude of compression, plastic beads with 2.0 mm 
thickness were employed and Group 5 (2.0 mm bead group, n=8) underwent 2.0-mm-
thick bead implantation with the same compression center as the 1.5-mm-thick bead 
implantation over the middle SMC.  
After the bead implantation or control procedure, the scalp was sutured.  
To examine the effects of compression release at different time points, Group 6 
(day 0 removal group, n=9) underwent a 1.5-mm-thick bead implantation over the middle 
SMC, followed by immediate bead removal, and Group 7 (day 3 removal group, n=7) 
received a 1.5-mm-thick bead implantation over the middle SMC, followed by delayed 
bead removal at post-operative (post-op) day 3. The behavioral results of these two 
groups were compared with those of the group undergoing persistent 1.5-mm-thick bead 
compression over the same area. 
2.3.4 Behavioral tests 
Forelimb-use asymmetry test (cylinder test): Rats were placed in a transparent 
cylinder, which is 30 cm high and 20 cm in diameter. Rats tend to rear and contact the 
wall of the cylinder with their forepaws spontaneously (Fig. 2.1). The numbers of wall 
contacts with the ipsilateral (unaffected), the contralateral (affected) and both limbs were 
recorded by a rater blind to the lesion side. Twenty consecutive behaviors were scored. 
The extent of forelimb-use asymmetry was calculated as ipsilateral limb use plus 1/2 the 
number of “both” contacts, divided by the total number of behaviors (equal to 20). Higher 
scores (>50%) indicate greater behavioral deficits (Schallert and Woodlee, 2005).  
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Figure 2.1: Example picture of a rat in the forelimb-use asymmetry test. 
Somatosensory asymmetry test: Rats were tested in their home cage. Adhesive 
labels (Avery adhesive backed labels, 113 mm2) were attached to the distal-radial aspect 
of both forelimbs (Fig. 2.2 A). Rats tend to remove these uncomfortable stimuli (Fig. 2.2 
B). The order of contact (i.e., left vs. right) was recorded in each of 4 trials to determine 
whether the rat showed a bias. If the animal showed a preference for removing the 
stimulus from one particular forelimb—that is, if the adhesive stimulus was contacted 
first on 3 or more of the trials—then additional tests were conducted to determine the 
magnitude of the somatosensory asymmetry. The size of the unbiased limb stimulus was 
progressively increased and, at the same time, the size of the biased limb stimulus was 
decreased by an equal amount (14.1 mm2). The ratio of the size of the unbiased limb 
stimulus relative to that of the biased limb stimulus was increased until the bias was 
neutralized, providing the magnitude of somatosensory asymmetry. A score was given to 
reflect the two levels between which the animal reversed the original order of contact. If 
the rat did not show any bias, a score of 0 was assigned for it. If the rat showed a bias 
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contralateral to the lesion, a negative score was given, while a positive score was 
assigned to represent a bias ipsilateral to the lesion. Higher scores indicate greater 
behavioral deficits (Schallert et al., 1982; Schallert and Whishaw, 1984; Schallert et al., 
2000; Schallert et al., 2002). 
 
 
Figure 2.2: Example pictures of a rat in the somatosensory asymmetry test. 
Foot-fault test: Animals were placed on an elevated grid floor (45 cm X 30 cm), 
2.5 cm higher than a solid base floor, with 2.5 cm X 2.5 cm diameter openings. When 
animals inaccurately placed a limb, the limb fell through one of the openings in the grid 
(Fig. 2.3). When the limb fell through and pulled back quickly without touching the solid 
base, the behavior was called a half fault and counted as 1 foot-fault score. If the limb fell 
through and touched the base for support, this situation was called a full fault and counted 
as 2 foot-fault scores. Both foot-fault scores and the number of total steps for both 
forelimbs with at least 40 movements in a trial, were measured. The asymmetry score 
was given by subtracting the percent of ipsilateral forelimb faults from the percent of 




Figure 2.3: Example picture of a rat in the foot-fault test.  
Tapered ledged beam test: A tapered beam, 165 cm long and 2 cm thick, was 
placed on top of a wider beam to create a tapered beam with 2 cm wide ledges on each 
side positioned 2 cm below the top of the beam surface. This arrangement allows rats 
traversing the beam to use the bottom ledge as a crutch when they misstep (Fig. 2.4). The 
ledged beam reduces the need for rapidly learning compensatory motor behaviors to 
prevent falling, and thus reveals behavioral deficits in the rats chronically. If a rat 
misstepped and its limb touched either side of the beam without using the ledge for 
support, it was counted as a half fault. If the rat misstepped onto the ledge, it was counted 
as a full fault. Both step faults and the number of total steps for each hind-limb over 5 
trials across the entire beam were measured. The asymmetry score was calculated by 
subtracting the percent of ipsilateral hind-limb faults from the percent of contralateral 




Figure 2.4: Example picture of a rat in the tapered ledged beam test.  
Vibrissae-evoked forelimb placing test: The rat was gently held by its torso, with 
the tested forelimb hanging freely, and the untested forelimb kept from placing by gentle 
pressure on the front of the limb. A same-side placing reaction (Fig. 2.5 A and B) was 
induced by slowly moving the ipsilateral vibrissae toward a countertop until the tip of the 
vibrissae made contact with the edge, thus eliciting a placing response in the ipsilateral 
forelimb (Barth et al., 1990a; Jones and Schallert, 1994; Schallert and Woodlee, 2005). 
Similarly, a cross-midline placing response (Fig. 2.5 C and D) was induced by turning the 
rat sideways and brushing its contralateral vibrissae against the surface of the table, thus 
eliciting a placing response in the opposite forelimb (Woodlee et al., 2005). A score was 
given indicating the percent of successful placing responses during 10 trials for both 
forelimbs in either of these two placing tests (Schallert et al., 2000; Schallert et al., 2002; 




Figure 2.5: Example pictures of a rat in the placing tests.  
(A and B) Examples of a successful (A) and a failed (B) placing response in the same-
side placing test. (C and D) Examples of a successful (C) and a failed (D) placing 
response in the cross-midling placing test.  
2.3.5 Tissue processing and analysis 
Rats were anesthetized with an overdose of pentobarbital (75 mg/kg, i.p.) and 
perfused through the left ventricle with neutral buffered 10% formalin as a fixative 
following vascular washout with a 0.1 M heparinized phosphate buffer rinse. Brains were 
removed and postfixed at 4oC in the same fixative.  
The brain tissue from rats sacrificed at post-op day 7 was processed, embedded 
and cut into seven 2-mm-thick coronal blocks. Six-µm-thick paraffin sections from each 
block containing the area of bead compression were obtained and stained with 
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hematoxylin and eosin (H&E) for evaluation of pathological changes. For in situ 
apoptosis detection, the paraffin sections were stained using terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) apoptosis tag kit (Chemicon) according to 
the manufacturer’s instructions and counter-stained with hematoxylin.  
The brains from rats sacrificed at post-op day 28 were cut into 50-µm-thick 
sections on a vibratome. Every fourth section was mounted on slides and stained with 
toluidine blue for examination of anatomical changes and location. The areas containing 
the compressive lesion were scanned into the computer. A schematic diagram of a cross 
section from the compressed area is shown in Figure 2.6. The cortex thicknesses at the 
compression center and the corresponding contralateral hemisphere were measured as 
lines ab and cd, respectively, in figure 2.6. The hemisphere widths for both the lesioned 
and corresponding contralateral unlesioned sides were measured as lines ef and gh, 
respectively, in figure 2.6. Both the hemisphere areas and the cortex areas for both the 
lesioned and corresponding contralateral unlesioned sides were measured by tracing the 
demarcation on the computer screen using an NIH image analysis program (ImageJ, 
NIH). The hemisphere volumes (mm3) and the cortex volumes (mm3) were calculated by 
multiplying the appropriate area by the section interval thickness. The data are presented 




Figure 2.6:  Schematic diagram of a cross section from the compressed area. 
2.3.6 Statistical analysis 
Statistical analyses were performed using SPSS 11.5 statistical software (SPSS, 
Inc., Chicago, Illinois, US). Repeated-measures analysis of variance (ANOVA) was 
applied to examine behavioral data across days, and the simple main effects at a specific 
test day were determined with one-way ANOVA. When there was a significant overall 
effect, post-hoc analyses were carried out. The anatomical data from different lesion 
groups were also compared by one-way ANOVA. Data are presented as mean ± standard 






e f g h 
 26
2.4 RESULTS 
2.4.1 SMC lesion extent and placement 
Figure 2.7 shows the brains removed 28 days after the 1.5-mm-thick bead 
compression over the anterior (Fig. 2.7 A), middle (Fig. 2.7 B) and posterior (Fig. 2.7 C) 
SMC, respectively. Sampling slices with Nissl staining from the group of 1.5-mm-thick 
bead compression over the middle SMC (Fig. 2.7 D) and the group of 2.0-mm-thick bead 
compression over the middle SMC (Fig. 2.7 E) are shown in Figure 2.7 as well. Both 
coronal sections were obtained at the site of the approximate compression center of each 
brain from the corresponding groups sacrificed 28 days after lesions. Both the 1.5-mm-
thick and the 2.0-mm-thick bead compression led to brain deformation, in which the 
midline shifted toward the contralateral side and the brain became wider.  
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Figure 2.7:  Histological images of brain compression. 
(A-C) Brains with 1.5-mm-thick bead compression over varied areas of the sensorimotor 
cortex (SMC). These brains were all removed 28 days after bead implantation. (A) 
Anterior SMC compression. (B) Middle SMC compression. (C) Posterior SMC 
compression. (D,E) Slices at the compression center with Nissl staining. These two slices 
were both sectioned from brains with bead compression for 28 days. (D) 1.5-mm-thick 
bead compression. (E) 2.0-mm-thick bead compression. (F-L) H&E staining and TUNEL 
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apoptosis assay. H&E staining images (200 times magnification) show different 
magnitudes of damage, which includes hemorrhage, edema and cell death to the brain 
tissue in representative slices from 1.5-mm-thick bead implantation (F); 1.5-mm-thick 
bead implantation followed by immediate removal (G); 1.5-mm-thick bead implantation 
followed by removal at post-op day 3 (H); 2.0-mm-thick bead implantation (I). All were 
sacrificed at post-op day 7. Panel J shows a higher magnification (400 times 
magnification) of a representative slice from the 2.0-mm-thick bead compression group, 
with arrow heads indicating samples of necrotic neurons. Hematoxylin and TUNEL 
counter staining (400 times magnification) shows few apoptosis signals even in the 2.0-
mm-thick bead implantation model, sacrificed at post-op day 7 (K). The arrow heads in 
panel K display samples of apoptotic neurons. Panel L shows a high magnification (1000 
times magnification) of dark brown apoptotic neurons. Scale bar = 1 mm (D,E); Scale bar 
= 100 µm (F-I), 50 µm (J,K), 20 µm (L). 
Table 2.1 shows the results for the lesioned hemisphere relative to the unlesioned 
hemisphere, including cortex thickness at the compression center, mean cortex thickness 
in the adjacent compression area, hemisphere width at the compression center, mean 
hemisphere width in the adjacent compression area, and the hemisphere and cortex 
volumes in the compression area. All data were collected from brains removed 28 days 
after lesions and subjected to Nissl staining. All three groups of 1.5-mm-thick bead 
implantation with varied compression locations showed less than 2 percent cortical tissue 
loss. One-way ANOVA indicated no significant differences among the anterior, middle 
and posterior SMC compression groups (F(2,13) = 0.201; p = 0.820). Compression 
induced by the 2.0-mm-thick bead over the middle SMC resulted in approximately 7 
percent of cortical tissue loss. Considering cortex thickness, one-way ANOVA showed 
no significant differences among the three 1.5-mm-thick bead implantation groups in 
both cortex thickness at the compression center (F(2,13) = 2.033; p = 0.171) and the 
mean cortex thickness in the compression area (F(2,13) = 3.562; p = 0.058). 2.0-mm-
thick bead compression over the middle SMC led to a significantly greater decrease of 
cortex thickness at the compression center, compared with 1.5-mm-thick bead 
compression over the same location (F(1,13) = 4.833; p < 0.05). As for the mean 
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hemisphere width in the compression area, no significant differences were found among 
the three 1.5mm thick bead implantation groups (F(2,13) = 1.960; p = 0.180). Also, no 
significant differences in mean hemisphere width were revealed between the groups of 
2.0-mm-thick and 1.5-mm-thick beads implanted over the middle SMC (F(1,13) = 0.125; 
p = 0.729). 
 
Table 2.1:  Histological analysis after brain compression. 
Ratios of cortex thickness at the compression center, the mean cortex thickness in the 
compression area, hemisphere width at the compression center, the mean hemisphere 
width in the compression area, hemisphere volume and cortex volume in the compression 
area of the lesion side to the contralateral side are shown from different lesion types, 
including 1.5-mm-thick bead implantation over the anterior SMC, middle SMC and 
posterior SMC, and 2.0-mm-thick bead implantation over the middle SMC. All the data 
were collected 28 days after surgeries with sections Nissl-stained. Data are mean ± SEM. 
 
To investigate early pathological changes following focal compression, 4 rats in 
each group were sacrificed at post-op day 7. H&E staining and TUNEL apoptosis assay 
were conducted. As shown in H&E stained sections (Fig. 2.2 F to I), hemorrhage, edema 
Ratio 
(Lesion/Contralateral) 1.5 mm Bead (An) 1.5 mm Bead (Mid) 1.5 mm Bead (Pos) 2.0 mm Bead (Mid)
Cortex thickness at the
compression center 
67.79%±0.060 55.86%±0.023 58.00%±0.053 43.74%±0.047 
Mean cortex thickness 78.60%±0.023 72.10%±0.009 74.00%±0.028 66.09%±0.029 
Hemisphere width at the
compression center 
109.84%±0.008 103.22%±0.025 103.13%±0.009 107.32%±0.012
Mean hemisphere width 108.29%±0.017 104.95%±0.021 102.58%±0.008 105.77%±0.012
Hemisphere volume 99.58%±0.002 96.58%±0.009 98.84%±0.004 93.93%±0.019 
Cortex volume 99.05%±0.009 98.01%±0.013 98.61%±0.013 93.20%±0.024 
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and necrosis were present in each lesion group, which varied with magnitude, and was 
related to the extent of compression. Under light microscopy, as shown in Figure 2.2 J, 
necrotic neurons could be identified as red neurons, exhibiting cytoplastic eosinophilia, 
or ghost neurons, with complete loss of hematoxylinophilia, due to the features of 
necrosis, including pyknosis, karyorrhexis and karyolysis (Garcia et al., 1995). 
Vacuolization was prominent in the tissue area adjacent to the compressive mass. A 
higher density of blood vessels was also found, presumably reflecting damage-induced 
angiogenesis. General pathological evaluation indicated that the 2.0-mm-thick bead 
compression led to greater brain tissue damage than the 1.5-mm-thick bead compression, 
while the 1.5-mm-thick bead compression released at post-op day 3 displayed reduced 
brain tissue damage compared with the 1.5-mm-thick bead that remained implanted. The 
1.5-mm-thick bead compression released immediately resulted in minor but notable brain 
tissue damage. With TUNEL staining, only few apoptotic cells were found even in the 
2.0-mm-thick bead compression group (Fig. 2.2 K and L), suggesting that little apoptosis 
is involved in such focal compression lesions. 
2.4.2 Behavioral deficits of compression are dependent on implant locations 
In the cylinder test at post-op day 4 as shown in Figure 2.8, one-way ANOVA 
among the four groups revealed a significant main effect (F(3,27) = 3.862; p < 0.05). 
Post-hoc analyses indicated a significant difference between the middle SMC bead 
implant group and the control group (F(1,17) = 8.303; p < 0.05). However, no significant 
differences were found either between the anterior group and the control (F(1,13) = 
0.011; p = 0.918) or between the posterior group and the control (F(1,13) = 0.478; p = 
0.502). Also, at post-op day 4, the middle SMC bead implant group showed significantly 
more behavioral deficits than the anterior SMC bead implant group (F(1,14) = 7.064; p < 
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0.05), but there were no significant differences between either the middle group and the 
posterior group (F(1,14) = 4.456; p = 0.053), or the anterior group and the posterior group 
(F(1,10) = 0.372; p = 0.556). Because focal compression over the middle SMC led to 
more consistent behavioral deficits, the following experiments used this procedure to 
investigate the influence of timing and magnitude on compressive effects.  
Figure 2.8:  Behavioral responses in rats with brain compression in varied locations.  
Animals with 1.5-mm-thick bead compression over the middle SMC, but not those 
undergoing either anterior or posterior SMC focal compression were found to exhibit 
significant forelimb-use asymmetry compared to the control. Data are mean ± SEM. * 
indicates a significant difference from control or between different conditions with p < 
0.05. 
2.4.3 Behavioral deficits are dependent on the timing of compression release  
Compared with the control group in the cylinder test (Fig. 2.9 A), the group with 
the 1.5-mm-thick bead removed at post-op day 3 showed significant behavioral deficits at 
post-op day 2 (F(1,14) = 7.762; p < 0.05), but no significant differences at post-op day 4 

























functional recovery. When removed immediately after implantation, the 1.5-mm-thick 
bead did not induce any behavioral deficits in the cylinder test at each time point 
compared with the control group.  
In the somatosensory asymmetry test (Fig. 2.9 B). One-way ANOVA showed that 
1.5-mm-thick bead implantation caused significant behavioral deficits at post-op day 7, 
compared with the control group (F(1,17) = 7.382; p < 0.05). Repeated-measures 
ANOVA showed significant differences between the group with the 1.5-mm-thick bead 
removed at post-op day 3 and the group with the 1.5-mm-thick bead left in place (F(1,15) 
= 6.810; p < 0.05). Simple main effects revealed significant group differences at post-op 
day 4 (F(1,15) = 12.937; p < 0.01). In contrast to the cylinder test results, the immediate 
bead removal group showed significant somatosensory asymmetry at post-op day 7, 
compared with the control group (F(1,16) = 8.965; p < 0.01), suggesting that even 
transient compression can cause at least some lasting, or delayed, behavioral deficits. 
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Figure 2.9: Behavioral responses in rats with brain compression released at different 
times.  
Forelimb-use asymmetry (A) and somatosensory asymmetry (B). 1.5-mm-thick bead 
implantation caused significant behavioral deficits compared to the control group in both 
the cylinder test and the somatosensory asymmetry test. Bead removal at post-op day 3 
resulted in improved functional recovery in both the cylinder test and the somatosensory 
asymmetry test. Bead implantation followed by immediate removal caused no behavioral 
deficits in the cylinder test, but significant deficits in the somatosensory asymmetry test. 
Data are mean ± SEM. * indicates a significant difference from control or between 

























































2.4.4 Behavioral deficits of compression depend on the magnitude of compression  
One-way ANOVA revealed that 2.0-mm-thick bead compression resulted in 
greater behavioral deficits than 1.5-mm-thick bead compression at post-op day 2 (F(1,12) 
= 5.626; p < 0.05) in the somatosensory asymmetry test (Fig. 2.10 A; F(1,16) = 4.739; p 
< 0.05), the foot-fault test (Fig. 2.10 B; F(1,14) = 6.792; p < 0.05), and the hind-limb 
ledged tapered beam test (Fig. 2.10 C; F(1,12) = 6.861; p < 0.05). The 1.5-mm-thick bead 
group did not show any placing deficits, while the 2.0-mm-thick bead implantation 
caused significant deficits in contralateral forelimb placing. In the same-side placing test 
(Fig. 2.10 D), repeated-measures ANOVA showed significant differences between the 
1.5-mm-thick bead group and the 2.0-mm-thick bead group (F(1,16) = 55.591; p < 0.001) 
as well as a significant time effect (F(6,96) = 24.581; p < 0.001) and a significant time by 
group effect (F(6,96) = 24.581; p < 0.001). Follow-up tests of simple main effects 
revealed significant group differences at post-op day 1 (p < 0.001), day 2 (p < 0.001), day 
3 (p < 0.01) and day 4 (p < 0.05). The cross-midline placing test also showed a similar 
behavioral pattern (Fig. 2.10 E). In repeated-measures ANOVA, there was a significant 
group effect (F(1,16) = 5.153; p < 0.05), a significant time effect (F(6,96) = 5.348; p < 
0.001) and a significant time by group effect (F(6,96) = 5.348; p < 0.001). Follow-up 
tests of simple main effects revealed significant group differences at post-op day 1 (p < 
0.01) and day 2 (p < 0.05). In the cylinder test, no significant differences were found 




Figure 2.10:  Behavioral responses in rats with different magnitudes of brain 
compression.  
Somatosensory asymmetry (A), foot-faults asymmetry (B), hind-limb faults asymmetry 
as measured in the tapered beam test (C), same-side placing (D) and cross-midline 
placing (E) with the contralateral forelimb following different size bead implantation. 
The 2.0-mm-thick bead was found to cause greater behavioral deficits than the 1.5-mm-
thick bead in all the above tests. Data are mean ± SEM. In A-C, a positive number 
represents a bias ipsilateral to the lesion and a negative number represents a bias 
contralateral to the lesison. * indicates a significant difference between different lesion 































































































































Besides the bead model that we used in this study, two other models of focal 
cerebral compression using different devices have been reported in the literature. One is 
the balloon model, used to examine the intracranial pressure and cerebral blood flow 
changes in compressed brain tissue (Abe et al., 1984; Douzinas et al., 1999; Im and Park, 
2002). Another one is the piston model, used to determine the pathological and 
behavioral effects of acute epidural pressure leading to transient cerebral ischemia 
(Kundrotiene et al., 2002; Kundrotiene et al., 2004b; Kundrotiene et al., 2004a; Moreira 
et al., 2005; Moreira et al., 2006; Moreira et al., 2007). In 2003, Chen et al. first 
developed this bead model and used it to investigate how epidural compression affects 
neuronal morphology. However, no gross behavioral deficits were detected (Chen et al., 
2003b). This bead model can well mimic mass lesions with the bead remaining implanted 
epidurally for a long time, which allows for the implementation of various interventions 
and chronic behavioral measurements using sensitive tests. Because location, duration 
and magnitude are the primary factors determining brain mass effects, we further 
modified the design of the bead by varying its thickness and adding a dent on the flat 
upper surface for more accurate orientation and more convenient translocation.  
The results of the present study suggest that displacement of brain tissue occurs as 
a result of its elastic property under the insult of focal compression. In general, the brain 
can adapt to compressive force through deformation (i.e., midline shift and extension 
within the skull). Our data showed that although the thickness of the cortex under 
compression shrinked significantly, only a small amount of brain tissue loss developed—
that was, 2% and 7% of tissue loss a month after 1.5-mm-thick and 2.0-mm-thick bead 
implantation, respectively. A previous study showed that total dendritic length as well as 
dendritic spines on all dendrites were reduced, while the densities of neurons and 
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capillaries increased following compression (Chen et al., 2003b). Based on the increased 
densities of neurons and vessels, it was concluded that no cell death was involved in the 
compression of particles 1.5 mm in thickness (Chen et al., 2003b). In our study, H&E 
staining revealed necrotic cell death and angiogenesis, suggesting ischemia and ischemia-
related neuroplasticity. In this case, H&E staining may be a sensitive method of detecting 
pathological changes.  
Previous findings of spine loss accompanied by brain compression suggest that 
synaptic function may be compromised (Chen et al., 2003b). In the present study, our 
main interest focused on the behavioral changes after focal compression. To detect the 
influence of location, magnitude and duration of brain compression on behavioral 
deficits, we changed one factor and fixed the others. We found that a bead implanted over 
the middle part of the SMC caused reliably detectable behavioral deficits, compared with 
implantation over either the anterior or the posterior part of the SMC, whereas the 
shrinkage of the cortical thickness and the loss of cortical volume revealed no significant 
differences among these three groups. Several previous studies have found that location 
could be an important variable in behavioral responses in different kinds of lesion 
models. Varying the location of brain injury in the region of the SMC produced different 
behavioral outcomes and delayed subcortical degenerative patterns that were influenced 
by pharmacological interventions (Barth et al., 1990b; Jones and Schallert, 1992). Baskin 
et al., using similar tests, recently showed insult-location-dependent behavioral variation 
in a mouse traumatic brain injury model. Trauma centered on the middle SMC location 
appeared to cause the most severe and persistent behavioral deficits (Baskin et al., 2003). 
Our data revealed that behavioral deficits depend on the magnitude of brain 
compression. In our experiment, the 2.0-mm-thick bead caused more brain tissue loss and 
greater behavioral deficits compared with the 1.5-mm-thick bead after implantation. 
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Note, though, that while both the 1.5-mm-thick and 2.0-mm-thick bead compression 
induced behavioral deficits in the cylinder test and the somatosensory asymmetry test, 
only the 2.0-mm-thick bead implantation caused dysfunction in the vibrissae-evoked 
placing test, which typically can detect only larger injuries. There is extensive evidence, 
of course, that behavioral deficits depend on the magnitude of subtotal injury. For 
example, a relationship exists between the extent of dopamine depletion and behavioral 
deficits in a parkinsonian animal model (Schallert and Tillerson, 2000; Bergstrom et al., 
2001), and also, behavioral asymmetries tend to rely on the size of the lesion in a focal 
cortical ischemia model (Lindner et al., 2003; Allred and Jones, 2004). Here, we show a 
relationship between behavioral changes and the extent of brain compression.  
Early removal following 1.5-mm-thick bead compression at post-op day 3 showed 
functional improvement, compared with persistent compression using the same size bead, 
suggesting that early release of brain compression may be beneficial to functional 
recovery. After the 1.5-mm-thick bead was removed at post-op day 3, the shape of the 
brain appeared to recover to its original state by post-op day 28. Concurrent with our 
behavioral findings, Chen’s recent study reported that decompression for 14 days resulted 
in near complete to partial recovery of the cortical thicknesses and the dendritic length of 
pyramidal neurons, and also, the recoverability was dependent on duration of preceding 
compression (Chen et al., 2004). It would be important in the future to assess whether 
motor experience might influence molecular, structural and functional outcome (Jones 
and Schallert, 1994; Keyvani and Schallert, 2002; Kleim et al., 2003). 
After a month’s observation, we found that rats with both 1.5-mm-thick and 2.0-
mm-thick bead compression showed only minor behavioral deficits and recovered within 
two weeks, suggesting a mild lesion pattern for this model. We removed the same area of 
skull as a control operation, which showed transient detectable behavioral asymmetries in 
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the somatosensory asymmetry test, but the response was normal in the cylinder test. This 
result is consistent with previous findings that even skull removal can result in behavioral 
asymmetries (Adams et al., 1994). The effects of transient brain compression were also 
investigated. Animals with transient 1.5-mm-thick bead implantation followed by 
immediate removal showed considerable behavioral asymmetries in the somatosensory 
asymmetry test, but no detectable deficits in the cylinder test, indicating that even 
transient compression can lead to detectable behavioral deficits. It may seem paradoxical 
that significant somatosensory asymmetry was detected in the immediate removal group, 
compared with the control at post-op day 7, while the day-3 removal group had recovered 
by day 7. The mechanism to explain this phenomenon remains obscure so far, although 
secondary damage may possibly play a role in exaggerating brain injury following 
transient compression through bead-removal induced swelling and ischemia initiated at a 
critical time point. Chen et al (2004) found that decompression after 3 days or months led 
to varied extent of recovery of the dendritic length. Perhaps removing the bead early after 
the implantation can be especially traumatic. Results from earlier investigations showed 
behavioral deficits up to 7 days on the beam walking test after transient focal 
compression with a piston for 30 min (Kundrotiene et al., 2002; Kundrotiene et al., 
2004b). Taken together, our behavioral data from control operations and transient focal 
compression indicate that the somatosensory asymmetry test is sensitive even for a slight 
insult to the SMC.  
The bead model discussed here may be applied in evaluating treatment effects on 
neuroplasticity after mass compression in brain tumors, hematoma and traumatic head 
injuries. Exogenous NGF has been reported to enhance restoration of the density of 
dendritic spines on pyramidal neurons subjected to compression (Chen et al., 2004). 
Treatments to remove compressive masses either by pharmaceuticals or by surgery may 
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not promote neuroplasticity or may even damage the self-repair mechanisms involved in 
mass lesions depending on the timing. The mild lesion pattern makes this model 
specifically suitable to examine directly whether therapies designed to shrink mass would 
adversely affect brain plasticity and functional recovery independent of mass reduction, 
thereby facilitating an improvement of therapeutic strategies.  
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Chapter 3:  Interruption of Functional Recovery by the NMDA 
Glutamate Antagonist MK-801 after Compression of the Sensorimotor 
Cortex 
This work is published in Experimental Neurology in 2006 (Yang et al., 2006b). 
3.1 ABSTRACT 
Glutamate antagonists have recently been shown to limit tumor growth, providing 
potential new therapeutic strategies against brain tumors. Here we demonstrate that long-
term systemic administration of the glutamate NMDA receptor antagonist MK801, after a 
delay, adversely reverses functional recovery in rats with compressive mass lesions of the 
sensorimotor cortex. Our data suggest that the controlled focal cortical compression 
model may be a valuable pre-clinical tool to screen compounds for the treatment of brain 
tumors. It may be possible to use this model to develop interventions that maintain anti-
cancer effects but with diminished harm to bystander tissue and brain plasticity. 
3.2 INTRODUCTION 
Recent findings suggest a correlation between extracellular glutamate release and 
glioma expansion, adding brain tumor to the wide variety of central nervous system 
(CNS) diseases that involve excitotoxicity, such as stroke (Benveniste et al., 1984; 
Butcher et al., 1990), traumatic brain injury (Faden et al., 1989), Parkinson’s disease and 
Alzheimer’s disease (Olney et al., 1990; Doble, 1999; Miguel-Hidalgo et al., 2002). 
Excitotoxicity facilitates brain tumor growth in part by actively killing normal tissue in 
the vicinity of the tumor, thereby, easing tumor growth (Ye and Sontheimer, 1999; 
Takano et al., 2001; Sontheimer, 2003). Blockage of either N-methyl-D-aspartate 
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(NMDA) or alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
subtype glutamate receptors limits glioma growth in vitro and in vivo, by inhibiting 
proliferation and migration of tumor cells as well as inducing tumor cell death (Rzeski et 
al., 2001; Takano et al., 2001; Ishiuchi et al., 2002). Thus, the development of novel, 
well-tolerated drugs to modulate glutamate release and activation of its receptors may 
provide therapeutic opportunities for brain cancers (Planells-Cases et al., 2002). 
There is contradictory evidence in a large body of literature on the role of 
glutamate antagonists, which can either facilitate (Faden et al., 1989; Barth et al., 1990a; 
Sun and Faden, 1995; Barth et al., 1998; Kundrotiene et al., 2004b) or inhibit (Barth et 
al., 1990a; Kozlowski et al., 1994; Kozlowski et al., 1997; Barth et al., 1998; Kozlowski 
and Schallert, 1998; Felt et al., 2002; Biegon et al., 2004) optimal functional outcome 
after brain injury. The underlying mechanisms of these discrepancies seem to be related 
to the pattern and time of drug delivery and which anti-glutamate compound is used. 
Since the anti-tumor efficacy of the anti-glutamate drugs is dependent on persistent 
depression of glutamate activity (Chung et al., 2005), long-term drug administration is 
likely required for the management of brain tumors.  
Assessment of quality of life has become increasingly important in clinical trials 
to evaluate the benefits and risks of new brain tumor treatments, while pre-clinical 
research on the functional impact of cancer treatment is scanty. Therefore, we sought to 
investigate the effects of long-term exposure of MK801, an NMDA glutamate antagonist, 
which is effective in slowing brain tumor growth (Rzeski et al., 2001; Takano et al., 
2001), on functional recovery from mass compression, partly characteristic of some 
rapid-expanding brain tumors. In order to disentangle the potential detrimental effects of 
an anti-tumor treatment on brain function from its beneficial mass reduction effects, an 
approach using epidural implantation of a plastic bead overlying the sensorimotor cortex 
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(SMC) was used (Yang et al., 2006c). This controlled mass compression model, without 
the expansion property of an actual tumor, allows us to directly examine whether a 
promising brain tumor treatment, such as MK801, might harm bystander tissue and brain 
plasticity. 
3.3 MATERIALS AND METHODS 
3.3.1 Subjects 
Twenty-seven male Sprague-Dawley rats, weighing 150-200 g were used in this 
study. Animals were randomly assigned to the following groups: (1) animals receiving 
bead implantation followed by 1 mg/kg MK801 (Sigma) i.p. (Bead+MK801, n=8) or (2) 
the same volume saline i.p. (Bead+Vehicle, n=7) and (3) animals undergoing control 
operations followed by 1 mg/kg MK801 i.p. (Control+MK801, n=6) or (4) saline i.p. 
(Control+Vehicle, n=6) beginning on post-operative (post-op) day 1, three times a week, 
until 4 weeks after surgery. Control animals were administered MK801 to determine 
whether the drug itself can cause detectable behavioral changes. All injections were given 
after behavioral testing to ensure that drug intoxication effects would not affect the test 
results.  
3.3.2 Experimental model 
The plastic hemispherical bead used for focal compression surgeries was 4.8 mm 
in diameter and 2.0 mm in thickness. The unilateral epidural bead implantation surgery 
(Chen et al., 2003b, 2004; Yang et al., 2006c) was performed as described in Chapter 2. 
The center of the bead was located 1.0 mm rostral to the bregma and 2.5 mm lateral to the 
midline. Control animals received all surgical procedures, including skull removal, 
except for bead implantation. 
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3.3.3 Behavioral tests 
Rats were dynamically evaluated for neurobehavioral deficits over a 4-week 
period. Behavioral tests included vibrissae-evoked forelimb placing tests (both same-side 
placing and cross-midline placing), a forelimb-use asymmetry test, and a somatosensory 
asymmetry test (Schallert et al., 2000; Schallert et al., 2002; Schallert and Woodlee, 
2005; Woodlee et al., 2005; Yang et al., 2006c), with method details described in Chapter 
2. 
3.3.4 Tissue processing and analysis 
Four weeks after the surgery, all rats were given a lethal dose of sodium 
pentobarbital anesthesia (75 mg/kg, i.p.) and perfused transcardially with neutral buffered 
10% formalin. The brain tissue was processed, embedded and cut into seven 2-mm-thick 
coronal blocks. Six-µm-thick paraffin sections from each block containing brain tissue 
under bead compression were obtained and stained with hematoxylin and eosin (H&E) 
for light microscopic examination and image analysis. The hemisphere volume and 
cortex thickness for both the affected and corresponding contralateral unaffected sides of 
the brain were measured with a Global Lab Image analysis program (Data Translation, 
Malboro, MA). The data are presented as the percentage of the affected side relative to 
the corresponding contralateral side for each parameter. Also, the pathological changes 
were evaluated. The paraffin sections were counter stained with TUNEL (Chemicon) and 
hematoxylin to determine whether apoptotic death is present in the lesion and affected by 
treatment.  
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3.3.5 Statistical Analysis 
Behavioral responses across time were analyzed statistically by a repeated-
measures ANOVA model, and the simple main effects at a specific test day were 
determined by a one-way ANOVA model, followed by the Tukey HSD test for post-hoc 
comparisons when appropriate. The histological data from two different treatment groups 
were compared with Student’s t-tests. Level of significance was set to p < 0.05.  
3.4 RESULTS 
Figure 3.1 A shows a representative slice obtained from the level of compression 
center with H&E staining from the brain with bead compression for 28 days. Bead 
compression caused slight loss of brain tissue and significant shrinkage of cortex 
thickness in the compression area, but no significant differences were found between the 
bead+MK801 and bead+vehicle groups. Also, no significant differences were revealed by 
more detailed pathological observation of H&E stained tissue sections, in which necrosis, 
edema and angiogenesis indicative of ischemia were found in both groups (Fig. 3.1 B and 
C). TUNEL apoptosis assay showed very few apoptotic cells in the focal compression 
area in either the bead+MK801 group or the bead+vehicle group (Fig. 3.1 D). 
Repeated-measures ANOVA revealed no statistically significant effects of 
MK801 in control-operated animals in all behavioral tests. Moreover, there were no 
significant differences between the control+MK801 group and the control+vehicle group 
at any time point. Therefore, these two groups were pooled and labeled as controls for all 
subsequent statistical analyses (Kozlowski et al., 1994; Kozlowski et al., 1997; 
Kozlowski and Schallert, 1998). Repeated-measures ANOVA showed significant 
treatment group differences among bead+MK801, bead+vehicle and control groups in 
both same-side placing (p < 0.001) and cross-midline placing (p < 0.01) tests. In the 
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same-side placing test (Fig. 3.1 E), both groups with bead implantation exhibited 
significant contralateral placing deficits at day 1 following surgery (p < 0.001), and the 
deficits persisted at day 2 (p < 0.001), day 3 (p < 0.001) and day 4 (p < 0.01), compared 
to the pooled control group. At day 7, no significant differences were found between 
either group with bead compression and controls. By day 14, all the bead-implanted 
animals completely recovered their placing abilities. The continuous administration of 
MK801 led to a reinstatement of placing deficits in the bead+MK801 group, which, in 
contrast, did not occur in the bead+vehicle group. At post-op day 18, the performance of 
the bead+MK801 group differed significantly from controls (p < 0.01), and further 
declined until the last testing day (day 28). A similar behavioral change pattern was also 
revealed in the cross-midline placing test (Fig. 3.1 F). Both groups with bead 
implantation displayed cross-midline placing deficits at post-op day 1 (p < 0.01) and day 
2 (p < 0.05), but at day 3, they were both not significantly different from the control 
group. A reinstatement of placing deficits in the bead+MK801 group commenced at day 
20, and became significant at day 24 (p < 0.05) compared with controls, lasting 
chronically until the end of the experiment. The proportion of animals in each treatment 
group exhibiting deficits in contralateral forelimb placing is shown in Table 3.1. In the 
forelimb-use as well as somatosensory asymmetry tests, animals in both the 
bead+MK801 and bead+vehicle groups displayed minor but significant behavioral 
asymmetries, which resolved within a week following surgery, compared with controls 
(data not shown). 
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Figure 3.1: Histological and behavioral examinations after MK801 administration in 
rats with brain compression.  
(A) Representative slice at the compression center with H&E staining, sectioned from a 
brain with bead compression for 28 days. Scale bar, 1 mm in A. (B, C) Photomicrographs 
with H&E staining (400 times magnification). H&E staining shows damage to the brain 
tissue, including necrotic neuronal death and edema in both B: bead+MK801 and C: 
bead+vehicle. Animals were sacrificed 4 weeks following bead implantation. Arrow 
heads indicate samples of necrotic neurons. Scale bar, 100 µm in B and C. (D) 
Photomicrograph with TUNEL and hematoxylin counter staining (400 times 
magnification). TUNEL apoptosis assay shows few apoptotic cells in both bead 
implantation groups, sacrificed 4 weeks after lesion. Scale bar, 100 µm in D. (E, F) 
Results of forelimb placing measurements. Percentages of successful placing responses 
are shown for the contralateral forelimb in both the same-side placing test (E) and the 
cross-midline placing test (F). Both bead+MK801 and bead+vehicle groups exhibited 
significant placing deficits following bead implantation. The bead+MK801 group 
displayed a significant reinstatement of the placing deficit after complete recovery from 
focal brain compression. Both of the two placing tests revealed a similar behavioral 
change pattern. * indicates a significant difference between the bead+MK801 and 
bead+vehicle groups with p < 0.05. 
 
Table 3.1:  Percentage of animals in each treatment group showing placing deficits. 
The majority of animals in the bead+MK801 group exhibited reinstated deficits in both 
the same-side placing and cross-midline placing tests, whereas, all the animals in the 




Placing type Duration of deficits 
Bead+MK801 Bead+Vehicle Control
Short-term 100% 100% 0% 
Same-side placing 
Long-term 100% 0% 0% 
Short-term 87.50% 57.14% 0% 
Cross-midline placing 
Long-term 62.50% 0% 0% 
 
3.5 DISCUSSION 
Chronic administration of the NMDA antagonist MK801 from an early stage 
following focal cortical compression did not affect the recovery rate, but instead resulted 
in a reinstatement of placing deficits after complete recovery. Although the drug 
administration regimen is different, the timing of the reinstatement of the functional 
deficits by MK801 is consistent with the previous findings in both adult and neonatal rats 
(Barth et al., 1990a; Kozlowski et al., 1994; Kozlowski and Schallert, 1998; Felt et al., 
2002), suggesting that long-term maintenance of glutamatergic activity at NMDA 
receptors plays a key role in use-dependent plasticity and post-lesional recovery of brain 
function regardless of whether the underlying mechanisms are related to changes in 
homotopic cortex dendritic arbors or to other events which may occur in the lesioned 
hemisphere. Recent findings demonstrate that overactivation of the glutamate receptors 
exists only shortly after brain injury (< 1 hour), and is followed by profound and 
persistent dysfunction (Biegon et al., 2004). Glutamate agonists administered 24 and 48 
hours after traumatic brain injury improve the restoration of neurological and cognitive 
function (Biegon et al., 2004). 
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Our histology results with H&E staining and TUNEL apoptosis assay, together 
with the behavioral data, reveal the mild lesion pattern for this focal compression model, 
which confirm our previous findings (Yang et al., 2006c), and indicate that the 
exaggeration of behavioral deficits induced by chronic MK801 administration may not be 
attributed to cell death, at least in the region surrounding the bead. It is possible that the 
histological assays used in this study were not sufficiently sensitive to detect changes in 
the compressed tissue following MK801 treatment, or that the changes disappeared and 
became undetectable after a 4-week period. Recent observations illustrate that NMDA 
antagonists can trigger apoptotic neurodegeneration in the developing brain (Ikonomidou 
et al., 1999; Olney et al., 2002) as well as an increase of neurodestruction in the mature 
brain undergoing slowly progressing neurodegeneration (Ikonomidou et al., 2000). 
Pursuit of compounds that would act as glutamate antagonists and have no 
harmful effects on brain plasticity may be warranted. Memantine, which is also an 
NMDA antagonist, has been reported to significantly attenuate brain tumor growth 
(Takano et al., 2001) and is clinically well tolerated (Parsons et al., 1999). Also, 
cytostatic agents that inhibit cystine uptake suppress glioma release of glutamate, but do 
not influence astrocytes or neurons (Chung et al., 2005). Our results support the use of a 
controlled focal cortical compression model to screen promising compounds pre-
clinically, which may lead to improved pharmaceutical designs that limit brain tumor 
growth without harm to bystander tissue and brain plasticity after injury potentially 
associated with tumor progression and aggressive therapy. 
 50
Chapter 4:  Local Fluorouracil Chemotherapy Interferes with Neural 
and Behavioral Recovery after Brain Tumor-like Mass Compression 
This work is published in Behavioural Brain Research in 2006 (Yang et al., 
2006a). 
4.1 ABSTRACT 
In this study, we investigated the impact of intracerebral delivery of 
chemotherapy on functional recovery from focal cortical tissue displacement, 
characteristic of brain tumors. Unilateral focal brain compression was induced by 
epidural implantation of an inverted hemisphere-shaped bead over the sensorimotor 
cortex. Microinjections of a total of 1 mg chemoagent fluorouracil or the same volume of 
saline were made into the compressed cortex. Behavioral tests of forelimb sensorimotor 
function were conducted during four weeks’ observation. Rats subjected to any of the 
three types of lesions, saline microinjection plus cortical compression, chemoagent 
microinjection alone, or chemoagent microinjection combined with cortical compression, 
demonstrated significant behavioral deficits in several sensorimotor tasks, compared with 
saline-microinjected control animals. In placing tests, behavioral deficits elicited by each 
single treatment were worsened by combined treatment with chemoagent microinjection 
and focal cortical compression. Concurrently, local delivery of chemoagent into the 
compressed cortex induced increased cortical tissue loss, necrosis and apoptosis. These 
data indicate that local chemotherapy exacerbates compression-induced neurological 
impairment, and a model of controlled focal cortical compression may provide a valuable 




Fluorouracil (5FU) is an antimetabolic drug. The mechanism of action of 5FU is 
associated with inhibition of thymidylate synthase and incorporation of 5FU into DNA 
and RNA, affecting cell proliferation and survival (Noordhuis et al., 2004). 5FU has been 
widely used in the investigation of interstitial chemotherapy of brain tumors. There are 
two potential reasons. First, 5FU is hydrophilic, and does not readily cross the blood 
brain barrier (BBB). When systemically administered, 5FU has very little effect on 
malignant gliomas and other tumors implanted in the brain (Shapiro, 1971; Levin et al., 
1984; Shapiro et al., 1992); however, it shows some effect on the same malignant brain 
tumors implanted in the flank (Levin et al., 1972; Neuwelt et al., 1984), indicating that its 
lack of effectiveness is due to its limited concentration inside the tumor. Direct drug 
delivery of chemotherapy such as 5FU to the brain tumor can increase the drug level in 
the tumor area and furthermore can decrease the systemic undesired side effects (Menei 
et al., 1996; Lemaire et al., 2001; Fournier et al., 2003; Menei et al., 2004). Second, 5FU 
has relatively less direct neurotoxicity, compared to other commonly used chemotherapy 
drugs. 5FU is a pyrimidine, which acts on the synthesis of nucleic acids, killing cells that 
are actively duplicating DNA (Menei et al., 1996). However, even systemic 
chemotherapy can lead to central neurotoxicity, such as cerebellar syndrome, seizures, 
aphasia, global motor weakness and bulbar palsy, as well as leukoencephalopathy and 
progressive dementia (Hook et al., 1992; Figueredo et al., 1995; Barbieux et al., 1996; 
Bygrave et al., 1998; Bofill et al., 2000; Pirzada et al., 2000; Elkiran et al., 2004). 
Therefore, there is a good reason to doubt whether regional chemotherapy can initiate 
functional impairment in a healthy brain, while in a damaged brain, whether it can 
exaggerate secondary degeneration and impede functional recovery following focal 
cortical tissue displacement characteristic of brain tumors.  
 52
Although in standard tumor implant models reducing tumor size by local 
chemotherapy will likely retard or prevent deterioration of function dramatically while 
limiting unwanted effects associated with systemic delivery, tumor shrinkage could mask 
treatment-related adverse effects on the integrity of brain tissue. Therefore, a model that 
holds tumor size constant independent of treatment may be useful to assess potential 
detrimental effects of tumor growth inhibitors on brain plasticity more directly. In this 
study, the chemoagent 5FU or saline was infused into the region surrounding a false 
tumor located in the sensorimotor cortex. Injury to the compressed brain, and recovery of 
function, were detected using sensitive behavioral tests.  
4.3 MATERIALS AND METHODS 
4.3.1 Animals  
A total of 41 adult male Sprague Dawley rats were used in this study. Twenty-five 
rats were randomly assigned to one of the four groups: 5FU+bead (n=7), saline+bead 
(n=6), 5FU only (n=6), and saline only (n=6), which were retained for four weeks while 
behavioral tests were conducted. Another 16 rats with 4 assigned to each of the same four 
groups were sacrificed 24 hours following surgery to assess the acute histological 
changes.  
4.3.2 Experimental model 
Rats were anesthetized with ketamine (90 mg/kg) and xylazine (10 mg/kg) 
administered intraperitoneally (i.p.). After the head was fixed on a stereotaxic frame 
(Kopf) and the skull was exposed, an elliptical hole over the sensorimotor cortex (SMC) 
with approximately 5.8 mm in long diameter and 3.8 mm in short diameter was drilled. 
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4.3.2.1 Local delivery of 5FU 
A total of 1 mg 5FU (solution containing 50 mg/ml 5FU dissolved in water for 
injection, purchased from pharmacy of the University of Texas at Austin) in a 20 µl 
volume was equally divided into three trajectory microinjections, delivered into the SMC, 
2.5 mm lateral to midline, and 2.5 mm deep below dura, with A/P coordinates at 2.5 mm, 
1.0 mm, and -0.5 mm respectively relative to bregma. To reduce fluid backflow, drug 
infusion was conducted slowly at a speed of 1 µl per min and the needle was retained in 
position for 3 mins followed by very slow withdrawal after each injection. The dose of 
5FU was selected based on literature, in which 5FU can shrink brain tumors at similar 
doses (Menei et al., 1996; Lemaire et al., 2001; Fournier et al., 2003). Microinjections 
with the same volume of saline served as a control operation.  
4.3.2.2 Bead implantation 
After intracerebral microinjections, the plastic hemispherical bead, which is 4.8 
mm in diameter and 2.0 mm in thickness, was implanted epidurally over the SMC, 
according to previous studies (Chen et al., 2003b, 2004; Yang et al., 2006b; Yang et al., 
2006c). The bead, with the flat surface facing upward, was fixed on the required 
coordinates with the center at 1.0 mm rostral to bregma and 2.5 mm lateral to midline 
(Fig. 4.1 A). Fig. 4.1 B shows a representative brain after 28 days of bead compression. 
4.3.3 Behavioral testing 
An array of behavioral tests sensitive to focal insults to the SMC, including two 
different types of vibrissae-evoked forelimb placing tests (same-side and cross-midline 
placing), as well as a forelimb-use asymmetry test and a somatosensory asymmetry test, 
 54
were performed before and after surgical procedures. Please refer to Chapter 2 for more 
method details. 
4.3.4 Histological assessment 
Rats were anesthetized and perfused intracardially with physiological saline 
solution followed by 4% paraformaldehyde. Brains were removed, processed, embedded 
in paraffin, and cut into seven 2-mm-thick coronal blocks (Fig. 4.1 B). Six-µm-thick 
sections taken approximately every 0.5 mm from each block containing the area of bead 
compression were stained with hematoxylin and eosin (H&E). A total of 12 equally 
spaced sections with 0.5 mm interval for each rat were imaged with 2.5 times 
magnification for lesion volume measurement. The hemisphere contours were traced on 
each coronal section and the areas of both hemispheres were measured using the MCID 
computer imaging analysis system (Imaging Research, Inc., St. Catharines, Ontario, 
Canada). The hemisphere volumes in the compression area were estimated by the sum of 
the values produced by multiplying the appropriate area by the section interval thickness. 
Lesion volume was presented as both an absolute volume of the tissue loss and a volume 
percentage of the lesioned hemisphere compared with the contralateral hemisphere. The 
compression center was defined as the most intensively compressed region of the brain as 
indicated in Fig. 4.1 B. To study the pathological characteristics and the morphological 
changes of the compressed brain tissue under local chemotherapy, H&E-stained brain 
tissue collected from the approximate compression center 24 hours or 28 days following 
bead compression with or without 5FU administration was examined. To study the 
impact of local chemotherapy on normal brain tissue, the 2-mm-thick coronal blocks 
were further cut until needle tracks were found. In situ apoptosis detection was conducted 
with the TUNEL ApopTag kit (Chemicon) in conjunction with hematoxylin 
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counterstaining. Serial five 6-µm-thick sections obtained at the approximate coronal level 
of the compression center were analyzed for each animal that received bead implantation 
with the presence or absence of 5FU delivery. For quantification of TUNEL 
immunoreactivity, images of TUNEL-immunostained coronal sections were scanned 
using a X20 objective (0.296 mm2 field of view) via the MCID program. The number of 
TUNEL positive cells was counted throughout the entire neocortex in the affected 
hemisphere after compression on each section. During the calculation, TUNEL positive 
cells were confirmed at a higher magnification (X40 objective). 
4.3.5 Statistical analysis 
The behavioral data from each test were subjected to an overall repeated-
measures ANOVA, followed by post-hoc analyses when appropriate. The histological 
data from two different treatment groups were compared with Student’s t-tests. Data are 
presented as mean ± standard error. 
4.4 RESULTS 
4.4.1 Local delivery of 5FU exaggerates brain tissue loss after brain compression 
The volume percentage of the compressed cerebral hemisphere relative to the 
contralateral hemisphere in the compression area was 96.2% for the saline+bead group 
and 91.6% for the 5FU+bead group after 28 days of bead compression. Student’s t-test 
indicated that 5FU treatment resulted in a significant increase of the volume of tissue loss 
after focal cortical compression (p < 0.05, Fig. 4.1 C). Fig. 4.1 D and E show 
representative H&E-stained slices collected at the approximate coronal center of the 
compression from brains removed 28 days after bead implantation with (Fig. 4.1 E) and 




Figure 4.1: Local chemotherapy exaggerates compression-induced tissue loss in the 
SMC.  
(A) Schematic dorsal view of epidural bead implantation over the SMC. (B) A 
representative brain following bead compression for 28 days. (C) Local chemotherapy 
leads to a significant increase in cortical tissue loss. (D, E) Representative H&E-stained 
brain slices collected at the approximate compression center from the saline+bead group 
(D) and the 5FU+bead group (E), respectively, 28 days after lesions. Scale bar=1mm in D 
and E. 
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4.4.2 Local delivery of 5FU induces elevated necrosis after brain compression 
Acute and chronic pathological changes were determined with H&E staining. 
Images (Fig. 4.2 A to D) were obtained at the approximate compression center, which 
was identified as the deepest region of the compression curve, with the same coronal 
location as the sections shown in Fig. 4.1 D and E. Following bead compression, lesions 
were barely visible under 100 power magnification in both the acute (Fig. 4.2 A) and 
chronic (Fig. 4.2 C) phases. Under 400 power magnification, sporadic red and ghost 
neurons due to necrosis, and edema, more evident in the acute phase, were found in the 
compression area compared to the corresponding contralateral area (data not shown). 
Compared with those undergoing only control injections into the compressed tissue, local 
delivery of 5FU induced a substantial decrease of the tissue density, representing an 
increase in the extent of necrosis in the compression area, concurrent with substantial 
hemorrhage and edema occurring at a very early stage (Fig. 4.2 B) and prominent 
vacuolation exhibited at a later stage (Fig. 4.2 D).  
4.4.3 5FU microinjection causes extended damage around the needle track 
5FU microinjection caused extensive acute hemorrhage and chronic vacuolation, 
with the increased extent of necrotic damage around the needle track, compared with 
saline microinjection (Fig. 4.2 E to H). Fig. 4.2 F and H indicate the lesion range 
produced by 5FU microinjections into normal brain tissue.  
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Figure 4.2:  Local chemotherapy induces increase in necrosis following either focal 
cortical compression or needle damage.  
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(A to D) Representative H&E-stained images under 100 times magnification collected at 
the approximate compression center in the lesioned hemisphere of rats sacrificed 24 
hours after saline+bead (A), or 5FU+bead (B); 28 days following saline+bead (C) or 
5FU+bead (D). Compression borders were included in panel A to D. (E to H) 
Representative H&E-stained images under 100 times magnification collected around the 
needle track in the lesioned hemisphere of rats sacrificed 24 hours after saline (E) or 5FU 
(F) microinjection; 28 days following saline (G) or 5FU (H) microinjection. Bar=100 µm 
in A.  
4.4.4 Local delivery of 5FU induces elevated apoptosis after brain compression 
In the TUNEL assay, very few TUNEL-positive cells were found after bead 
compression alone in both the acute (Fig. 4.3 A) and chronic (Fig. 4.3 C) phases. A 
significant 5FU-induced increase in the total number of apoptotic cells in the compressed 
cortex was observed after 24 hours (p < 0.001, Fig. 4.3 A, B, and E) as well as 28 days (p 




Figure 4.3:  Local chemotherapy leads to increase in apoptosis following focal cortical 
compression.  
(A to D) Representative TUNEL&Hematoxylin-counterstained images under 200 times 
magnification collected at the approximate compression center in the lesioned 
hemisphere of rats sacrificed 24 hours after saline+bead (A), or 5FU+bead (B); 28 days 
following saline+bead (C) or 5FU+bead (D). Compression borders were included in all 
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four images. Magnified views (400 times magnification) of the selected TUNEL-positive 
cells are shown in panel A and D. No TUNEL-positive cells were found in panel C. (E) 
The apoptotic cell number was significantly increased in the compressed cortex with the 
presence of chemotreatment both 24 hours and 28 days after lesions. Bar=100 µm in A. * 
indicates a significant difference between different conditions with p < 0.05.  
4.4.5 Local delivery of 5FU exacerbates compression-induced functional deficits 
In the same-side placing test (Fig. 4.4 A), saline-treated control animals did not 
show any placing deficit. Other animals that received 5FU treatment alone (p < 0.001), or 
saline injection plus bead compression (p < 0.001), or 5FU treatment plus bead 
compression (p < 0.001), all displayed significant placing deficits, compared to control 
animals, respectively. Animals that received 5FU treatment in combination with bead 
compression demonstrated significantly greater placing impairments, when compared 
with either animals that underwent saline microinjection combined with bead 
compression (p < 0.001) or those receiving 5FU treatment alone (p < 0.01). 
In the cross-midline placing test (Fig. 4.4 B), no animals in the non-bead control 
group showed deficits, in contrast to some animals in the saline+bead group; however, 
these groups did not differ significantly. Both the 5FU group (p < 0.05) and the 
5FU+bead group (p < 0.001) showed significant deficits, when respectively compared 
with the control group. Also, animals in the 5FU+bead group displayed significantly 
worse placing impairments than those either in the saline+bead group (p < 0.001) or in 
the 5FU group (p < 0.01).  
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Figure 4.4:  Local chemotherapy exacerbates compression-induced placing deficits. 
The 5FU+bead group showed significant worse placing deficits than either the 
saline+bead group or the 5FU group, in both the same-side placing test (A) and the cross-
midline placing test (B). * indicates a significant difference between any of the other 
lesion groups and the saline-treated control; + indicates a significant difference between 
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the 5FU+bead group and the saline+bead group; # indicates a significant difference 
between the 5FU+bead group and the 5FU group.  
In the forelimb-use task (Fig. 4.5 A), saline microinjection led to a transient 
behavioral asymmetry, revealed by analysis of within-subjects effect (time effect) in 
repeated-measures ANOVA (p < 0.05), implicating that even the needle damage can 
detectably affect the behavioral performance. Each of the other treatment groups, 
including the 5FU group (p < 0.01), the saline+bead group (p < 0.01), and the 5FU+bead 
group (p < 0.001), showed a significant difference compared to the control group. 
Forelimb-use asymmetry in the 5FU+bead group was significantly more severe than in 
the saline+bead group (p < 0.01), but the 5FU+bead and the 5FU groups did not differ.  
In the forelimb somatosensory asymmetry test (Fig. 4.5 B), animals that received 
saline microinjection alone did not show any impairment. The saline+bead and the 
control group did not differ overall, although the two groups were significantly different 
from each other at day 2 (p < 0.01) and day 3 (p < 0.05). Animals that received either 
5FU treatment alone (p < 0.01) or both 5FU treatment and bead compression (p < 0.001) 
displayed significant deficits, when compared with control animals. The 5FU+bead group 
showed a significantly increased somatosensory deficit relative to the saline+bead group 
(p < 0.01), but no significant difference relative to the 5FU group.  
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Figure 4.5:  Local chemotherapy exacerbates compression-induced behavioral deficits in 
both the forelimb-use and the forelimb somatosensory asymmetry tests.  
The 5FU+bead group demonstrated significantly greater asymmetries than the 
saline+bead group, but no significant differences compared to the 5FU group, in both the 
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forelimb-use asymmetry test (A) and the somatosensory asymmetry test (B). * indicates a 
significant difference from control; + indicates a significant difference between the 
5FU+bead group and the saline+bead group. 
4.5 DISCUSSION 
The neurotoxicity or disruption of neuroplasticity associated with the aggressive 
anti-cancer regimens potentially makes treatment a source of brain insult together with 
the tumor itself. Although radiation and chemotherapy are often blamed in the clinic for 
the accompanied neurological and cognitive side effects (Shapiro and Young, 1984; 
Macdonald, 1991; Vigliani et al., 1999), little preclinical research has addressed 
treatment impact specifically on non-tumor tissue. Here, we demonstrate that under 
conditions of focal cortical compression, which controls for drug induced changes in 
expansion or shrinkage of mass, local delivery of chemotherapy exacerbates functional 
impairments.  
Because most brain tumors do not tend to metastasize or spread to other parts of 
the body, the newly renovated local chemotherapy carried out through various delivery 
devices may be an effective way to reduce the systemic side effects and increase the 
amount of available drug in the tumor area. However, to date, although more specific 
drug delivery pathways for cancer treatment are being pursued, drug distribution to the 
surrounding and remote normal brain tissue may be unavoidable, and remains a potential 
concern. To our knowledge, there are no published data indicating the extent of 5FU 
diffusion after intracerebral microinjections. It would be interesting to investigate 
whether mechanical compression can influence the interstitial diffusion of 5FU in brain 
tissue. It is possible that diffusion could be more limited in compressed tissue, but still 
the drug might diffuse beyond the immediate peri-compression brain region. It remains to 
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be determined whether the adverse effects of 5FU include compromise to remote brain 
regions in this model. 
5FU has been widely used in local chemotherapy research (Menei et al., 1996; 
Lemaire et al., 2001; Fournier et al., 2003; Menei et al., 2004), in part because the 
frequency of neurotoxicity following its systemic administration is generally low. The 
dose of 5FU (1 mg per rat) applied regionally in the present study is roughly comparable 
to that being used to shrink brain tumors in rats in previous reports (Menei et al., 1996; 
Lemaire et al., 2001; Fournier et al., 2003).  
Consistent with our prior findings (Yang et al., 2006b; Yang et al., 2006c), the 
2.0-mm-thick bead compression produced mild injury. Not only local delivery of 5FU 
into the compressed brain exacerbated functional deficits, but 5FU into the normal brain 
did too. Histologically, 5FU significantly increased the loss of brain tissue following 
brain compression. 5FU induced significant vacuole formation suggesting a severe 
degree of cell necrosis, and also, apoptotic neurons were present both in the compressed 
area and around the needle. Previous observations demonstrate that metabolites of 5FU 
can induce vacuolation due to myelin splitting and destruction, and cause 
necrosis/softening-like change as well (Okeda et al., 1984; Okeda et al., 1988; Okeda et 
al., 1990; Akiba et al., 1996). Although myelin is more vulnerable than neurons, these 
pathological changes can develop where the toxic substance readily deposits and 
accumulates (Okeda et al., 1984). In addition, the central nervous system is among the 
organs that 5FU tends to be retained over long time periods (Zhang et al., 1992). 
Furthermore, when examining the effects of chemotherapeutic agents in combination 
with osmotic blood-brain barrier (BBB) modification, remarkable neurotoxicity was 
found, suggesting that limited entry of drug into the brain by an intact BBB may account 
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for the reduced neurotoxicity associated with the usual systemic administration of most 
chemotherapeutic agents (Neuwelt et al., 1983a; Neuwelt et al., 1983b).  
Although local delivery of chemotherapy drugs has been widely investigated, 
neurotoxicity has not been reported at the preclinical level (Menei et al., 1996). However, 
when it was applied to clinical trials, worsening of preexisting neurological symptoms 
was found (Menei et al., 2004). This problem exists extensively in brain cancer 
therapeutic development, in part because of the lack of functional outcome measurement 
in the preclinical evaluation of treatment effects. Gross observations, such as measure of 
body weight, feeding activity and locomotion, are not sufficient to reveal the changes in 
brain function. More importantly, in growing-tumor transplant models, the therapeutic 
effects of tumor shrinkage per se may obscure anti-plasticity or other harm to 
surrounding brain tissue. With a mild lesion pattern and without the invasive and growing 
properties of an actual tumor, controlled mass compression models can allow 
investigators to detect directly the potential adverse effects of brain tumor treatment on 
neuroplastic mechanisms.  
Our data suggest that compressed brain tissue may be more vulnerable to 
chemodrug-induced impairment. Therefore, it is important to choose the optimal time to 
initiate chemotherapy. It is possible that chemotherapy carried out after neurosurgical 
decompression and delayed until surgically induced edema and blood-brain barrier 
opening have resolved may lessen the intensity of chemo-associated neural damage. 
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Chapter 5:  Sensorimotor Deficits Associated with Brain Tumor 
Progression and Tumor-induced Brain Plasticity Mechanisms  
This work is published in Experimental Neurology in 2007 (Yang et al., 2007b). 
5.1 ABSTRACT 
The objective of this study was to investigate functional deficits and reactive peri-
tumoral brain plasticity events in glioma-bearing rats. 9L gliosarcoma cells were 
implanted into the forelimb region of the sensorimotor cortex in Fischer rats. Control 
animals underwent the same operation without tumor implantation. Sensitive tests for 
detecting sensorimotor dysfunction, including forelimb-use asymmetry, somatosensory 
asymmetry, and vibrissae-evoked forelimb placing tests, were conducted. We found that 
tumor-bearing animals exhibited significant composite behavioral deficits on day 14 post-
tumor injection compared to surgical controls. With the assistance of magnetic resonance 
imaging, we demonstrated a significant correlation between tumor volume and magnitude 
of somatosensory asymmetry, indicating that the somatosensory asymmetry test can 
provide an effective and efficient means to measure and predict tumor progression. 
Histopathological assessments were performed after the rats were sacrificed 14 days 
following tumor implantation. Immunostaining revealed that densities of microtubule-
associated protein 2, glial fibrillary acid protein, von Willebrand factor, and 
synaptophysin were all significantly upregulated in the peri-tumoral area, compared to 
the corresponding region in surgical controls, suggesting synaptic plasticity, astrocyte 
activation and angiogenesis in response to tumor insult. Understanding the behavioral and 
bystander cellular events associated with tumor progression may lead to improved 
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evaluation and development of new brain tumor treatments that promote, or at least do 
not interfere with, functional adaptation. 
5.2 INTRODUCTION 
Functional assessment of cancer therapy is essential in translational research and 
the first step is to establish a simple method for measurement of behavioral changes in 
animal tumor models. This study employed an array of sensorimotor behavioral tests to 
determine focal functional deficits in rats following implantation of glioma cells into the 
forelimb region of the sensorimotor cortex (SMC). Due to the variabilities in both tumor 
growth and behavioral response, a closer analysis using magnetic resonance imaging 
(MRI) was conducted to examine the correlation between tumor size and functional 
impairment.  
Both clinical observation and experimental research demonstrate the lack of 
severe functional deficits until the late stage when the tumor grows large, suggesting 
tolerance to tumor growth (Whittle and Marston, 1997; Yang et al., 2007b). Cerebral 
ischemia (Stroemer et al., 1992, 1993; Parent et al., 2002; Zhang et al., 2004b; Zhang et 
al., 2004a; Zhang et al., 2007a; Zhang et al., 2007b), mechanical compression 
(Kundrotiene et al., 2002; Kundrotiene et al., 2004b; Moreira et al., 2005; Moreira et al., 
2006; Yang et al., 2006b; Yang et al., 2006c; Yang et al., 2006a; Moreira et al., 2007), 
denervation (Gomez-Pinilla et al., 1992; Kadish and Van Groen, 2003) and excitotoxicity 
(Pollard et al., 1994) all induce brain plasticity that likely fosters functional recovery 
(Cramer and Chopp, 2000; Keyvani and Schallert, 2002). Brain plasticity may be most 
effective when the injury is minor and slowly increases over time, as observed in models 
of progressive neural degeneration (Fleming et al., 2005). Tumors likewise may gradually 
upregulate compensatory events, leading to their “stealth” nature. Peri-tumoral plasticity 
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may be vulnerable to tumor resection or anti-mitotic, anti-angiogenic, anti-growth factor 
and related treatments used to reduce brain tumor expansion. Normal brain cells, 
especially progenitor cells and oligodendrocytes, are more susceptible to chemotoxicity 
than cancer cells, and systemic administration of chemotherapeutic agents leads to 
reduced cell division and increased cell death in the adult mouse brain even long after 
drug exposure (Dietrich et al., 2006). Understanding how peri-tumoral neurons resist 
dying is important, as protection of the surrounding normal tissue and preservation of 
function is a major goal and a great challenge in glioma management. To begin to address 
this issue, markers for neurons, astrocytes, endothelial cells, and synaptogenesis were 
used to examine reactive peri-tumoral plasticity in the rat glioma implantation model.  
5.3 MATERIALS AND METHODS 
5.3.1 Experiment 1 
The goal of Experiment 1 was to examine forelimb sensorimotor function during 
the growth of tumors placed in the forelimb region of the sensorimotor cortex, and to 
investigate peri-tumoral plasticity-related events using immunohistochemistry.  
5.3.1.1 Animals  
A total of 18 adult male Fischer rats (Charles River Breeding, Wilmington, MA) 
weighing 180-250 g were used in Experiment 1.  
5.3.1.2 Experimental model 
Animals were randomly assigned to either the tumor-bearing group (n=9) or the 
control group (n=9).  
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9L gliosarcoma cell culture: 9L gliosarcoma cells (ATCC, Manassas, VA, USA) 
were maintained in monolayer culture (37°C, 5% CO2, 95% O2) in minimum essential 
media (MEM) with Eagle’s salts, supplemented with 10% fetal bovine serum, penicillin 
and streptomycin (Gibco, Grand Island, NY). Cells were subcultured and used for 
implantation when they reached an exponential phase of growth. To harvest, cells were 
incubated with 0.05% trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA, 0.53 mM, 
Gibco) for 5 min, and then MEM was added to make a single cell suspension. After the 
suspension was centrifuged at 1000 rpm (4°C) for 5 min, the media was removed and the 
cells were re-suspended in phosphate buffered saline (PBS). Cell viability was 
determined by trypan blue exclusion (non-viable cells stain blue). The number of 
unstained cells was counted using a hemacytometer under a microscrope and then the 
suspension was diluted with PBS to a final concentration of 107 cells/ml (Chopp et al., 
1996a; Chopp et al., 1996b; Jiang et al., 1997; Jiang et al., 1998). 
9L cell implantation in Fischer rats: Rats were anesthetized with ketamine (80 
mg/kg, i.p.) and xylazine (13 mg/kg, i.p.) and then placed in a stereotaxic device. After 
the scalp was incised and the cranium was exposed, a circular craniotomy, 2 mm in 
diameter, was made over the parietal cortex, 1.0 mm anterior to the bregma, and 2.5 mm 
lateral to the midline. Fifty thousand 9L gliosarcoma cells in 5 µl PBS were injected 
intracerebrally with a 10 µl Hamilton syringe to a depth of 2.5 mm beneath the dura 
during a 5-min interval (Chopp et al., 1996a; Chopp et al., 1996b; Jiang et al., 1997; Jiang 
et al., 1998). The needle was then retracted over a 6-min period. The craniotomy was 
covered with a piece of polyvinyl chloride film glued to the surrounding intact bone. The 
incision was closed with 4-0 silk sutures (Ethicon, Somerville, NJ).  
Control animals were treated identically to the tumor-implanted rats, having scalp 
incision, skull removal, needle insertion and withdrawal, but without tumor cell injection.  
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5.3.1.3 Behavioral testing 
Behavioral tests, including forelimb-use asymmetry, somatosensory asymmetry, 
and vibrissae-evoked forelimb placing tests, were carried out before and after surgical 
procedures. Please refer to the method details in Chapter 2.  
5.3.1.4 Histological assessment 
Tissue preparation: The tumor-bearing animals dying during the experiment were 
subjected to immediate sacrifice. Rats surviving until day 14 after tumor implantation 
were sacrificed at day 14. Rats were anesthetized and perfused intracardially with 
physiological saline solution followed by 4% paraformaldehyde. Brains were removed, 
processed, embedded in paraffin, and cut into seven 2-mm-thick coronal blocks.  
Measurement of tumor volume: Six-µm-thick coronal sections taken 
approximately every 0.5 mm from each block containing the tumor were stained with 
hematoxylin and eosin (H&E). H&E-stained sections were viewed with 2.5 times 
magnification and were scanned into the computer. The tumor area (mm2) was measured 
by tracing the demarcation of the tumor on the computer screen using the Global Lab 
Image analysis program (Data Translation, Marlboro, MA). The volume of the tumor 
(mm3) was estimated by summing the values produced by multiplying the respective 
tumor area by the section interval thickness.  
Immunofluorescence staining: Microtubule-associated protein 2 (MAP2), glial 
fibrillary acid protein (GFAP), von Willebrand factor (vWF), and synaptophysin were 
used as markers for neurons, astrocytes, endothelial cells, and synaptogenesis, 
respectively. 
A series of 6-µm-thick sections at 50 µm intervals were cut from the block 
containing the maximum cross-sectional tumor area. Double immunofluorescence 
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staining of MAP2 (mouse monoclonal, 1:200 dilution; Chemicon, Temecula, CA) with 
GFAP (rabbit polyclonal, 1:10,000 dilution; Dako, Carpenteria, CA) and double 
immunofluorescence staining of vWF (rabbit polyclonal, 1:400 dilution; Dako, 
Carpinteria, CA) with synaptophysin (mouse monoclonal, 1:1,000 dilution; Chemicon, 
Temecula, CA) were carried out on the 6-µm-thick sections. Fluorochromes fluorescein 
isothiocyanate (FITC; Jackson Immuno.) and Cy3 (Jackson Immuno.) were used for 
double-label imunoreactivity. The sections were counterstained with 4’,6-diamidino-2-
phenylindole (DAPI, Dako).  
After dehydration, sections were boiled in 1% citric acid buffer (PH 6.0) for 10 
min, and cooled down to room temperature. Subsequently, the sections were incubated in 
1% BSA to block the non-specific signals. The sections were incubated overnight at 4 oC 
in primary antibody (anti-MAP2 or anti-vWF antibody), followed by incubation with 
FITC-conjugated secondary antibody for 1 h at room temperature. The sections were 
incubated with primary antibody (anti-GFAP or anti-synaptophysin antibody) overnight 
at 4 oC and subsequently with Cy3-conjugated secondary antibody at room temperature 
for 1 h. Each of the above steps was followed by four 5-min rinses in PBS. The sections 
were counterstained with DAPI. Finally, the sections were mounted with Vectashield 
Hardset medium (Vector). Sections were visualized under a fluorescent microscope.  
Quantification of immunofluorescence: Semi-quantitative measurements of 
MAP2, GFAP, vWF and synaptophysin immunoreactivity were conducted on five 6-µm-
thick coronal sections that contain the tumor from each tumor-bearing brain and on five 
sections in the same region as the tumor from each surgical control. Images of 
corresponding immunostained sections were visualized at 400 times magnification with a 
fluorescent microscope and analyzed with MCID image analysis program. For 
quantification of immunoreactivity of MAP2, GFAP, and synaptophysin, five fields from 
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the peri-tumoral area of tumor-bearing animals and five fields from the operated 
hemisphere of control animals were selected. Densities of MAP2, GFAP, and 
synaptophysin (% of positive pixel) were calculated by dividing the positive pixels 
measured in the peri-tumoral area and the similar region in controls by the field of view 
(327680 pixels), respectively. For quantification of immunoreactivity of vWF, five fields 
from the tumors, five fields from the peri-tumoral areas, and another five fields from the 
surgical controls were selected. Density of vWF (% of positive pixel) was calculated by 
dividing the positive pixels measured in the tumor, the peri-tumoral area, and the similar 
region in controls by the field of view (327680 pixels). The corresponding values were 
averaged for each animal.  
5.3.1.5 Statistical analysis 
Raw scores from the four behavioral tests, including forelimb-use asymmetry, 
magnitude of somatosensory asymmetry, same-side placing and cross-midline placing, 
were converted to make all the testing outcomes consistent with higher scores indicating 
greater functional deficits, and then standardized with the following formula: 
 
where ky  is the mean and kσ̂  is the standard deviation of yi,k, i = 1, 2,…, N.  
Composite scores were produced by summing the four standardized behavioral 
scores and then adding 4 to avoid the occurrence of negative numbers (Schallert and 
Lindner, 1990; Lu et al., 2003).  
Repeated-measures ANOVA was applied to examine behavioral data across time. 
One-way ANOVA was used to examine behavioral differences between the two 
experimental groups at each specific time point. The immunofluorescent data of MAP2, 
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GFAP, and synaptophysin from the peri-tumoral areas and from the corresponding areas 
in surgical controls were compared with Student’s t-tests, respectively. The 
immunofluorescent data of vWF from the tumors and the peri-tumoral areas were 
compared with the corresponding areas in controls with Student’s t-tests, respectively. 
Data are presented as mean ± standard error.  
5.3.2 Experiment 2 
The goal of Experiment 2 was to determine the correlation between the magnitude 
of somatosensory asymmetry and the brain tumor volume dynamically measured by MRI. 
5.3.2.1 Animals, experimental model, and behavioral testing 
Seven animals received the same 9L gliosarcoma cell implantation surgery, and 
somatosensory asymmetry test as in Experiment 1. The behavioral tests were conducted 
immediately prior to MRI measurements at day 6, 12, and 16 after tumor implantation. 
5.3.2.2 MRI measurement 
MRI measurements were performed using a 7 T, 20 cm bore superconducting 
magnet (Magnex Scientific, Abingdon, UK) interfaced to a BRUKER console (Billerica, 
MA, USA). During the imaging procedure, the rat was fixed with ear bars and was fitted 
with a nose mask for anesthesia using a gas mixture of N2O (69%), O2 (30%) and 
Halothane or Isoflurane (0.75-1%). One of two standard magnetic resonance contrast 
agents (MRCA) was administered via tail vein based on availability: Gadomer-17, or 
gadolinium-diethylanetriamine pentaacetic acid (Gd-DTPA), with the dosage for both 
agents 250 µmol/kg, in a 0.15 ml bolus. High-resolution proton spin-lattice relaxation 
time (T1)-weighted images were obtained using multislice (27 slices) spin-echo 
[repetition time (TR) = 1000 ms, time to echo (TE) = 7.5 ms, 4 averages] sequences with 
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a 0.5 mm slice thickness, 32 mm field of view (FOV), and 256 x 192 matrix before and 
after administration of MRCA, with imaging time approximately 13 min for each 
sequence.  
All MR images were reconstructed using a 128 x 128 matrix. Image analysis was 
performed with “eigentool” software (Peck et al., 1992; Peck et al., 1996; Ewing et al., 
2006). Using the postcontrast T1-weighted image, each slice was examined for the 
presence of tumor. If a tumor was detected, regions of interest (ROIs) were outlined 
manually and filled, and the areas were measured. The volume of the tumor in the slice 
was calculated by multiplying the area by the slice thickness, and all such volumes were 
summed, thus yielding an estimate of the total tumor volume. 
5.3.2.3 Statistical analysis 
A multiple regression analysis was conducted to determine the relationship 
between tumor volume (independent variable) and behavioral score (dependent variable) 
after adjusting for time (covariate). The significance levels (p) of tumor volume as well 
as time in the multiple regression model were calculated. The correlation coefficient (R) 
was calculated. An equation Y = b0 + Σ biXi was produced to summarize the model, in 
which Y is the predicted value of behavioral score, Xi represents all the independent 
variables, including tumor volume and time, bi represents regression coefficients, and b0 
is the value of Y when all X are zero.  
 77
5.4 RESULTS 
5.4.1 Experiment 1 
5.4.1.1 Late onset of significant behavioral deficits in 9L glioma-bearing rats 
Fischer rats implanted with 5 x 104 9L glioma cells usually die within 14 to 17 
days. In this study, two tumor-bearing animals died at day 11 and 14 respectively, and the 
rest of them were still alive at day 14 after tumor implantation. All surviving animals 
were sacrificed after behavioral testing at day 14.  
Both repeated-measures ANOVA and one-way ANOVA showed no changes in 
the general activity of the tumor-bearing rats whose test results were collected. Near-
death animals could not perform the behavioral tests. In the somatosensory asymmetry 
test, both the percentage of the trials that the adhesive label on the ipsilateral limb was 
contacted first and the asymmetry score, are presented. When the percentage of trials on 
which the ipsilateral label was contacted first was considered (Fig. 5.1 A), all surviving 
rats at day 14 displayed a marked bias for contacting the label on the ipsilateral forelimb. 
Repeated-measures ANOVA revealed a significant time effect (F (6, 84) = 3.378; p < 
0.01). One-way ANOVA showed significant differences between the tumor-bearing 
group and the control group at day 14 after tumor implantation (F (1, 14) = 7.828; p < 
0.05). In terms of the magnitude of the somatosensory asymmetry (Fig. 5.1 B), all 
surviving rats at day 14 exhibited an asymmetry with a score as much as, or higher than, 
2.5. Repeated-measures ANOVA showed a significant time effect (F (6, 84) = 6.124; p < 
0.001), and a significant time by group effect (F (6, 84) = 6.578; p < 0.001). One-way 
ANOVA showed that the tumor-bearing animals displayed significant behavioral deficits 
at day 14 (F (1, 14) = 41.702; p < 0.001) in comparison with control animals. In the 
 78
same-side placing test (Fig. 5.1 C), two tumor-bearing animals exhibited mild behavioral 
deficits after surgery, followed by complete recovery within a week, but one of them lost 
all ability to place its contralateral limb at day 11, and the deficits persisted at day 14. 
However, one-way ANOVA showed that the average performance of the tumor-bearing 
group was not significantly different from control subjects at any time point. In the cross-
midline placing test (Fig. 5.1 D), the same two tumor-bearing rats displayed minor 
behavioral deficits after surgery as they did in the same-side placing test, and they both 
recovered completely before day 4 post-tumor implantation. Two rats in the tumor-
bearing group showed severe placing deficits from day 11 on, and so did another rat at 
day 14 post-tumor implantation. Repeated-measures ANOVA revealed a significant time 
effect (F (6, 84) = 2.490; p < 0.05), and a significant time by group effect (F (6, 84) = 
2.490; p < 0.05). One-way ANOVA showed that tumor implantation was associated with 
significant behavioral deficits at day 14 (F (1, 14) = 5.801; p < 0.05), compared with the 
control procedure. Note that all animals involved in this experiment placed 100% 
successfully with both of their forelimbs in the baseline testing, and the tumor 
implantation did not influence the placing ability of their ipsilateral forelimbs. In the 
forelimb-use asymmetry test (Fig. 5.1 E), one-way ANOVA showed no significant 
differences in the average performance between glioma-bearing rats and control-operated 
animals throughout the testing period. The test results from the four behavioral tasks were 
integrated to produce a composite score for each animal at each time point (Fig. 5.1 F). 
Repeated-measures ANOVA revealed a significant time effect (F (6, 84) = 4.070; p < 
0.01), and a significant time by group interaction (F (6, 84) = 4.460; p < 0.01). One-way 
ANOVA showed that tumor progression elicited significant behavioral deficits at day 14 
post-tumor implantation (F (1, 14) = 12.224; p < 0.01), as compared to control. 
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Figure 5.1:  Behavioral deficits associated with brain tumor progression.  
Significant differences were found between the tumor-bearing group and the control 
group at day 14 after tumor implantation in both percentage of ipsilateral contact of 
adhesive label stimuli (A) and magnitude of the somatosensory asymmetry (B). In the 
same-side placing test (C), the average performance of the tumor-bearing group was not 
significantly different from that of the control group at any time point. In the cross-
midline placing test (D), tumor growth caused significant behavioral deficits at day 14 
post tumor cell injection, compared with the control procedure. In the forelimb-use 
asymmetry test (E), there were no significant differences in the average performance 
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between glioma-bearing rats and control-operated animals throughout the testing period. 
Raw scores from the four behavioral tests, including forelimb-use asymmetry, magnitude 
of somatosensory asymmetry, same-side placing and cross-midline placing, were 
integrated to produce a composite score for each animal at each time point (F). Tumor 
progression elicited significant composite neurological deficits at day 14, as compared to 
control. * indicates significant difference between tumor-bearing animals and surgical 
controls at the respective time point with p < 0.05. 
5.4.1.2 Tumor volume and placement 
Post-mortem inspection of the tumor-bearing brains confirmed the presence of 
large striato-cortical tumors in all 9 tumor-implanted animals. The tumor volume was 
114.4 ± 35.6 mm3. Variable midline shift was noted. In tumor-bearing brains, dark purple 
tumor masses were clearly detected in H&E-stained sections. The peri-tumoral area was 
identified as an area around the main tumor mass with approximately 0.5 to 1 mm in 
depth, which was slightly darker than the surrounding normal tissue, consisting of mixed 
small multi-focal tumors and non-tumor brain tissue.  
All 9 control animals had normal brains except for mild damage related to either 
the burr hole or the needle tract.  
5.4.1.3 Reactive peri-tumoral brain plastic events  
Quantitative evaluation of the immunohistochemical reactivity was performed by 
optical density measurements. With DAPI nuclear counterstaining (in blue, Fig. 5.2 A 
and E, and Fig. 5.3 A and E), the tumor was well demarcated from the surrounding brain 
tissue, characterized by high nuclear density. The peri-tumoral area contained scattered 
small foci of tumor. Neither MAP2 (green, Fig. 5.2 F) nor GFAP (red, Fig. 5.2 G) 
immunoreactivity was found in 9L tumor cells. Student’s t-tests revealed a significant 
increase in both MAP2 (t (16) = 5.539; p < 0.001; Fig. 5.2 I) and GFAP (t (16) = 4.083; p 
< 0.01; Fig. 5.2 J) expression in the peri-tumoral area (Fig. 5.2 F and G), compared with 
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the similar region in surgical controls (Fig. 5.2 B and C). Fig. 5.2 D is derived from the 
merging of Fig. 5.2 A, B with C. Fig. 5.2 E, F and G were merged to produce Fig. 5.2 H. 
Student’s t-tests revealed significant increases in vascular density in the tumor region (t 
(16) = 4.705; p < 0.001; Fig. 5.3 F and I) and the peri-tumoral area (t (16) = 4.269; p < 
0.01; Fig. 5.3 F and I), compared with the control (Fig. 5.3 B and I), as indicated by the 
immunoreactivity for vWF (green). We were unable to detect synaptophysin-positive 
staining (red) in 9L tumor cells (Fig. 5.3 G). The peri-tumoral area displayed significantly 
increased staining for synaptophysin (t (16) = 3.739; p < 0.01; Fig. 5.3 G and J), in 
comparison with the corresponding area in surgical controls (Fig. 5.3 C and J). Fig. 5.3 D 
was generated by the merger of Fig. 5.3 A, B and C. Fig. 5.3 E, F and G were merged to 
form Fig. 5.3 H. 
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Figure 5.2:  Significant increase in MAP2 and GFAP expression in the peri-tumoral 
area.  
Representative images of MAP2 (green) and GFAP (red) double immunostaining with 
DAPI (blue) counterstaining under 200 times magnification collected from the tumor 
hemisphere (E-H) and the similar region in controls (A-D), respectively. There was a 
significant increase in both MAP2 (I) and GFAP (J) expression in the peri-tumoral area, 




Figure 5.3:  Significant increase in vWF and synaptophysin expression in the peri-
tumoral area.  
Representative images of vWF (green) and synaptophysin (red) double immunostaining 
with DAPI (blue) counterstaining under 200 times magnification collected from the 
tumor hemisphere (E-H) and the similar region in controls (A-D), respectively. The 
vascular density in both the tumor region and the peri-tumoral area significantly 
increased compared with the corresponding region in controls (I), as indicated by the 
immunoreactivity for vWF. The peri-tumoral area also displayed significantly increased 
staining for synaptophysin in comparison with the control (J). Bar = 100 µm in A. * p < 
0.05 versus controls.  
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5.4.2 Experiment 2 
5.4.2.1 Significant correlation between magnitude of somatosensory asymmetry and 
brain tumor volume 
Fig. 5.4 A illustrates the tumor volumes in 7 rats repeatedly measured by MRI at 
different time points. Each line represents an individual rat. Rat # 1, 2, 3 died at day 14 
post-tumor implantation, while rat # 4, 5, 6, 7 stayed alive until day 16. Although there 
was great individual variability in tumor growth rate, the tumors all followed a consistent 
growth pattern, with faster increase in volume in the later stages.  
Behavioral tests were carried out on the same day but prior to MRI measurements 
to avoid the influence of anesthesia on the behavioral performance. The tumor-bearing 
rats exhibited a faster behavioral deterioration in the late stage, with a similar trend to 
tumor progression. Multiple regression analysis showed that the p-value of tumor volume 
after adjusting for time was 0.002, while the p-value of time after adjusting for tumor 
volume was 0.813, indicating that tumor volume was a strong predictor, while time was a 
poor predictor of the behavioral response in the model. The correlation coefficient 
between tumor volume and behavioral test score was 0.775, indicating a high degree of 
correlation and a good fit to a linear model. The correlation coefficient without 
considering time (R = 0.774) was similar to that with time as a covariate (R = 0.775), also 
suggesting that time made little contribution to the regression model. Therefore, the time 
covariate can reasonably be neglected from the regression model. Data were shown in 
Fig. 5.4 B using bivariate plots with the X axis representing tumor volume and the Y axis 
representing behavioral score. The equation Y = -0.261 + 0.081 X was produced to 




Figure 5.4:  Significant correlation between tumor volume and magnitude of 
somatosensory asymmetry.  
(A) Tumor volumes measured by MRI at different time points in 7 glioma-bearing rats. 
(B) Somatosensory asymmetry scores corresponding to tumor volumes. A regression line 
based on the equation Y = -0.261 + 0.081 X fits the data well. 
5.5 DISCUSSION 
We found that 9L glioma-bearing rats did not exhibit significant functional 
deficits until the presence of very large tumors. Our results are consistent with clinical 
observations and preclinical studies. Despite the large tumor volume, the development of 
focal neurological deficits is rarely evident before manifestations of raised intracerebral 
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pressure (Whittle and Marston, 1997). Whittle and Marston reported that only occasional 
problems with locomotor function, grooming or general behavioral functions were 
observed in several hundred cases of rodents implanted with gliomas when the tumors 
were not very large, and that a subtle progressive loss of motor function was evident in 
the rat C6 striatal implantation model from 12 days post-implantation during a 22-day 
test period, detected with the staircase test (Whittle and Marston, 1997).  
Among the four behavioral tests that we used in Experiment 1, the somatosensory 
asymmetry test was the most sensitive for detecting tumor-elicited behavioral deficits. All 
animals with tumors displayed significant deficits in this test, whereas in the other three 
tests, only a portion of animals did. The composite behavioral deficit score was 
influenced primarily by the somatosensory asymmetry. Therefore, in Experiment 2, we 
examined the correlation between tumor volume and magnitude of somatosensory 
asymmetry and we found a significant correlation between the two variables with the 
coefficient of correlation 0.775. Every tumor has a unique growth pattern. In addition to 
growth rate and size, individual tumors may vary in their extension to neighboring 
locations, the degree of brain distortion and hydrocephalus, and invasion to the 
ventricular system. The timing and extent of neuroplasticity-related processes may 
considerably vary too. Furthermore, there is a subclinical tumor growth stage. These and 
other events could have degraded the early relationship between behavior and MRI 
assessment and could explain why, prior to Day 14, the average behavioral deficit was 
not significant.  
Potential mechanisms by which peri-tumoral neurons are damaged and eventually 
lost are incompletely understood. In the rat C6 striatal implantation model, concurrent 
metabolic dysregulation and neuroreceptor alterations may contribute to peri-tumoral 
brain dysfunction (Whittle and Kelly, 2001). An investigation into human diagnostic 
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resection specimens and postmortem cases of gliomas revealed neuronal loss as well as a 
sequence of morphological disarray and stress responses in surviving neurons in cerebral 
cortex infiltrated by diffuse astrocytoma (Goel et al., 2003). In many ways, a brain tumor 
might be regarded as an injury, not unlike other types of cell loss, and thus would be 
expected to induce neuroplasticity. The relatively slow growth pattern of brain tumors 
may share adaptive mechanisms associated with slow degenerative diseases in which 
adaptive mechanisms prevent early clinical signs. Previous studies showed neurogenic 
response of the subventricular zone (SVZ) to malignant brain tumors grown in the 
striatum (Duntsch et al., 2005; Glass et al., 2005; Bexell et al., 2007). In the present 
study, we observed putative reactive peri-tumoral plasticity-related changes, including 
markers linked to synaptogenesis, astrocyte activation and angiogenesis.  
MAP2 is a cytoskeletal protein localized in the neuronal dendritic compartment. 
MAP2 plays an important role in neuronal migration and neurite outgrowth by organizing 
microtubules in developing neurons both for axonal and dendritic morphogenesis (Teng 
et al., 2001). MAP2 expression coincides with dendritic outgrowth, branching, and post-
lesion dendritic remodeling, suggesting that this protein plays a crucial role in plasticity 
(Johnson and Jope, 1992). Suppression of MAP2 inhibits neurite formation (Dinsmore 
and Solomon, 1991; Caceres et al., 1992). A previous study demonstrated that MAP2 
increased in hippocampal granule cell dendrites following kainite-induced seizures and 
neuronal loss, suggesting that MAP2 contributes to the stabilization of dendrites after 
axonal denervation and eventually to the development of new spines and postsynaptic 
specializations during the reinnervation process (Pollard et al., 1994). Glioma cells 
release excessive amounts of glutamate and cause excitotoxicity in the vicinity of the 
tumor (Ye and Sontheimer, 1999; Takano et al., 2001; Sontheimer, 2003). In the current 
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study, the peri-tumoral increase in MAP2 immunoreactivity may implicate dendritic 
sprouting and postsynaptic alterations as compensatory responses to tumor insult.  
The peri-tumoral increase in GFAP immunoreactivity indicates astrocyte 
activation. Reactive gliosis has been described as an important outcome of an injury to 
the nervous system, and plays a crucial role in clearing degenerating terminals 
(Bechmann and Nitsch, 1997), providing trophic factors (Rowntree and Kolb, 1997; 
Baba, 1998; Dong and Benveniste, 2001; Keyvani and Schallert, 2002; Kleim et al., 
2003), and reestablishing a proper microenvironment for neural tissue repair (Shao and 
McCarthy, 1994; Aldskogius et al., 1999).  
vWF is an endothelial marker, used as an index of vascular density. The peri-
tumoral increase in microvessel density reflects the angiogenic process. Normal 
angiogenesis occurs in developing or healing tissues to provide an adequate supply of 
nutrients (Papetti and Herman, 2002). Inhibition of angiogenesis impedes astroglial 
proliferation and brain repair (Krum and Khaibullina, 2003). Although tumor-induced 
angiogenesis is a pathological condition, it mimics the process of normal angiogenesis, 
which remodels established primitive networks of blood vessels to support metabolic 
demands (Papetti and Herman, 2002). Angiogenesis in normal tissue surrounding the 
tumor may be an adaptive change in response to tissue hypoxia/ischemia and may 
contribute to tissue recovery. Using a novel three-dimensional quantitative method to 
analyze laser-scanned confocal microscopy images of dextran-labeled cerebral 
microvessels, Jiang et al. found significant angiogenesis in tumor and adjacent tissue, 
identified by increases in the number of vessel branch points coincident with a decrease 
in the mean vessel length (Jiang et al., 2005). 
Synaptophysin is a presynaptic vesicle protein that may be a marker of synaptic 
density (Leclerc et al., 1989; Masliah et al., 1990; Masliah et al., 1991). An increase in 
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synaptophysin immunoreactivity has been found in the cortex surrounding an area of 
infarction (Stroemer et al., 1992). Upregulated synaptophysin staining density occurs in 
the hippocampus following unilateral enhorhinal cortex lesions in both mice and rats, 
which may be an indication of terminal sprouting and new synapse formation (Kadish 
and Van Groen, 2003). It is possible that the peri-tumoral increase in synaptophysin 
immunoreactivity in the present study reflects axonal sprouting, presynaptic alterations 
and/or synaptogenesis in response to tumor challenge.  
Since we did not control tumor size or block any peri-tumoral events, it remains 
to be determined whether adaptive mechanisms could prevent or slow the onset of 
neurological deficits. 
In summary, using sensitive behavioral tests, we observed that following tumor 
implantation in the sensorimotor cortex, rats showed significant functional deficits, but 
only when tumor growth was extensive. The significant correlation between tumor 
volume and somatosensory impairment suggests that behavioral markers might help to 
gauge the extent of tumor progression. We detected a number of peri-tumoral 
pathological changes that could be reasonably linked to synaptic plasticity, astrocyte 
activation and angiogenesis. It is possible that peri-tumoral and/or remotely located 
mechanisms of reactive plasticity may compensate for tumor-associated insult, partially 
contributing to subclinical tumor extension. Improvements in functional assessment as 
well as in evaluating pathological events and compensatory adaptations in addition to 
tumor size may provide useful adjuncts to evaluate potential treatment strategies. 
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Chapter 6:  Functional Outcome after Antiangiogenic Treatment in a 
Mouse Glioma Model  
This work is published in Behavioral Brain Research in 2007 (Yang et al., 2007a). 
6.1 ABSTRACT 
The objective of the current study was to investigate the functional outcome after 
treatment with a novel antiangiogenesis regimen, which is a combination of monoclonal 
antibodies against both vascular endothelial growth factor receptor (VEGFR)-1 (MF1) 
and VEGFR-2 (DC101) in the orthotopic mouse model of human U87 glioma. We found 
that the combination antibody therapy retarded tumor progression and delayed the onset 
of significant behavioral deficits. Histologically, tumor necrosis and apoptosis were 
increased and tumor cell proliferation was decreased after treatment. In clinical trials for 
novel interventions, functional end points typically are included in the assessment of 
potential efficacy. Because certain interventions that successfully treat tumor progression 
in animal models might interfere with compensatory neuroplasticity, functional 
measurement may be valuable for improving the clinical relevance of translational brain 
tumor research. 
6.2 INTRODUCTION 
Angiogenesis is a process of growing new vessels by remodeling the preexisting 
ones (Papetti and Herman, 2002). Normal angiogenesis ensures an adequate supply of 
oxygen and nutrients for developing or healing tissues (Papetti and Herman, 2002). 
Tumor-induced angiogenesis is a pathological condition in order for tumor growth and 
propagation to occur, which mimics normal angiogenesis with the same aim of satisfying 
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the metabolic demands of a tissue, (Carmeliet and Jain, 2000; Papetti and Herman, 2002). 
However, tumor-induced neovessels exhibit abnormal ultrastructures, which are dilated 
and tortuous, and exceptionally permeant due to transcellular gaps and fragmented 
membranes (Papetti and Herman, 2002; Jain, 2005). Two main factors contribute to the 
leakiness of tumor vessels: vascular endothelial growth factor (VEGF) and angiopoietin 
(Ang)-2. VEGF not only increases tumor vessel density (Plate et al., 1992; Takahashi et 
al., 1995), but also increases vascular permeability (Senger et al., 1983; Kevil et al., 
1998; Tse et al., 2003), which eases the penetration of tumor cells (Papetti and Herman, 
2002). Ang2 antagonizes the Ang1-Tie2 pathway to allow the preexisting vessels to 
revert to an unstable and plastic state, and to maintain the plastic state in the newly 
formed vessels, thus facilitating VEGF-induced vessel growth (Stratmann et al., 1998; 
Holash et al., 1999; Zagzag et al., 1999; Audero et al., 2001; Ding et al., 2001; Papetti 
and Herman, 2002; Tse et al., 2003).  
Antiangiogenic therapy has been considered an alternative or complementary 
paradigm to conventional cancer treatments. Antiangiogenic therapy is aimed at 
restraining tumor progression, instead of eliminating all the tumor cells, and is especially 
suited for administration during the course of the tumor-dormant state (Kohn and Liotta, 
1995; Mikkelsen, 1998). However, antiangiogenic treatment has been reported to impede 
brain repair in a wound lesion model (Krum and Khaibullina, 2003), and therefore may 
potentially reduce restorative neuroplastic processes associated with tumor and its 
treatments. 
An initial step in developing animal models that could potentially be used to 
assess the relative effects of different treatment strategies on brain tumor growth vs. 
neuroplasticity should include assessment of neurological outcome. The primary goal of 
this study was to use a standard glioma model together with a currently promising 
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treatment to determine the potential sensitivity of behavioral assays in detecting 
dysfunction. We investigated the influence of antiangiogenic treatment on brain function 
in glioma-bearing mice. The combined inhibition of VEGFR1 and VEGFR2 signaling is 
a powerful antiangiogenic treatment, which has been shown to be more effective than 
targeting either VEGFR1 or VEGFR2 alone in other cancer types (Lyden et al., 2001). 
Our results demonstrate that the combination antibody therapy retarded tumor 
progression and delayed the onset of significant behavioral deficits without detectably 
affecting brain function adversely in the dormant stages of tumor development.  
6.3 MATERIALS AND METHODS 
6.3.1 Cell culture 
The U87 human glioma cell line was grown in minimum essential media (MEM) 
with Earle’s salts, supplemented with 10% fetal bovine serum, 0.2% phenol red, and 1% 
each of L-glutamine, MEM sodium pyruvate, nonessential amino acid, and penicillin and 
streptomycin (Invitrogen Corp., Carlsbad, CA), and incubated in a 5% CO2 humidified 
atmosphere at 37oC. Prior to intracranial implantation, cells were dispersed with 0.05% 
trypsin/EDTA (Invitrogen Corp.) and adjusted to a final concentration of 108 cells/ml in 
PBS. 
6.3.2 Experimental model 
A total of 23 nude mice (Nu/Nu athymic; Charles River Breeding Laboratories, 
Wilmington, MA) with a body weight of 15 to 25 g were employed in this study. Fifteen 
animals received brain implantation of 5X105 U87 tumor cells and 8 animals were 
assigned to sham surgery. Five microliters of U87 cells (5X105 cells) were slowly 
injected into the sensorimotor cortex (SMC) at the following coordinates: 2.0 mm lateral 
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from the midline, 1.0 mm anterior to the bregma, and 2.5 mm ventral to dura (Jiang et al., 
2005). Sham animals were treated identically to the tumor-implanted mice, having scalp 
incision, but without skull removal. 
6.3.3 Antiangiogenic treatment regimen 
Seven U87 tumor-bearing mice underwent i.p. injections of MF1 (400 µg/mice) 
and DC101 (800 µg/mice) every other day from day 8 to day 14 after tumor implantation. 
The doses of the two agents were based on previous literature (Prewett et al., 1999; 
Kunkel et al., 2001; Lyden et al., 2001) as well as on information from the manufacturer 
(Imclone Inc., New York).  
6.3.4 Histopathology 
6.3.4.1 Tissue preparation 
After animals were perfused with 4% paraformaldehyde, brains were removed 
and cut into 1-mm-thick blocks which then were processed and embedded in paraffin. 
Six-µm-thick sections were further cut from each of the blocks containing the tumor.  
To examine the effect of monoclonal antibodies (mAbs) against VEGFR-1 (MF1) 
and VEGFR-2 (DC101) on tumor vessel density, animals implanted with U87 cells were 
administered fluorescein isothiocyanate (FITC)-conjugated dextran (2x106 molecular 
weight, Sigma, St. Louis, MO; 1 ml of 5 mg/ml) intravenously (i.v.) 2 mins before they 
were sacrificed. The brain tissue was cut on a vibratome into 100-µm sections which 
were used for fluorescent confocal microscopy. 
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6.3.4.2 Measurement of tumor volume 
Six-µm-thick coronal sections obtained serially at 0.5 mm intervals from each of 
the blocks containing the tumor were stained with H&E for calculation of tumor size. 
Please refer to Chapter 5 for the detailed method of tumor volume calculation. 
6.3.4.3 Immunohistochemistry 
Ki67 (rabbit monoclonal, IgG antiboday, 1:300 dilution; Lab Vision, CA) 
immunostaining was performed. Ki67 antigen is the prototypic cell cycle related nuclear 
protein, expressed in proliferating cells. Six-µm-thick paraffin sections were incubated 
with a primary antibody followed by a biotinylated secondary antibody. 3’3’-
diaminobenzidine-tetrahydrochloride (DAB; Sigma) was used to routinely detect reaction 
product, which can be visualized directly by bright-field light.  
In situ apoptosis assay was conducted by examining fragmented DNA on paraffin 
embedded tissue sections with the TUNEL ApopTag kit (Chemicon) in conjunction with 
hematoxylin counterstaining. 
6.3.4.4 Quantification 
One hundred-µm-thick sections containing the U87 tumor, obtained from animals 
administered with FITC-dextran, were imaged using a confocal microscope, and analyzed 
with MCID program. For measurement of vascular density, five fields of view from the 
tumor area in each of the five coronal sections per animal were analyzed and the positive 
area was measured. Vascular density (% of positive pixel) was calculated by dividing the 
positive pixels by the field of view. With fluorescent confocal microscopy, aberrant 
vascular structures inside the tumor were identified as regions of high vessel density 
and/or the presence of abnormally large vessels. The volume of the regions containing 
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aberrant vasculature was calculated by multiplying the appropriate area by the section 
interval thickness. 
For quantification of immunoreactivity of TUNEL and Ki67, images of 
corresponding immunostained 6-µm-thick coronal sections were scanned using either a 
X40 objective (0.074 mm2 field of view, for Ki67) or a X20 objective (0.296 mm2 field 
of view, for TUNEL) via the MCID computer imaging analysis system. For each 
immunostaining type, five fields of view per section and five sections per animal that 
contain the tumor were quantified. The numbers of TUNEL positive or Ki67 positive 
cells were counted in the tumor area within each section. The total number of positive 
cells was divided by the total tissue area to determine cell density (cell number/mm2) and 
the value was averaged for each animal.  
6.3.5 Behavioral testing (rearing) 
Mice were placed in a Plexiglas cylinder, 15 cm in height with a diameter of 10 
cm (Baskin et al., 2003; Starkey et al., 2005; Wells et al., 2005). An experimenter scored 
independent use of the left or right forepaw, or simultaneous use of both forepaws, for 
contacting the wall of the cylinder during a full rear, to initiate a weight-shifting 
movement or to regain center of gravity while moving laterally in a vertical posture along 
the wall. Twenty consecutive instances of limb use behavior were recorded and the 
asymmetry score was calculated as percent use of the ipsilateral (unaffected) forelimb 
minus that of the contralateral (affected) forelimb.  
6.3.6 Statistical analysis 
Histology data from two sampled groups were compared with Student’s t-tests. 
Repeated measures ANOVA was used to evaluate functional performance across testing 
days and one-way ANOVA was used to examine differences among the means of several 
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different groups at each specific time point. When there was a significant overall effect, 
post-hoc tests were carried out to compare all groups of subjects with each other. All data 
are presented as mean ± standard error. 
6.4 RESULTS 
6.4.1 Delayed onset of significant functional deficits in U87 glioma-bearing mice 
treated with MF1 and DC101  
Unlike the U87 tumor control group, in which only 2 out of 8 animals were still 
alive at day 29, all of the animals in the MF1+DC101-treated U87 tumor group were 
alive at day 29. In the rearing test (Fig. 6.1), U87 glioma-bearing mice without 
MF1+DC101 treatment exhibited significant behavioral deficits at day 27, compared with 
either tumor-bearing animals receiving MF1+DC101 treatment (p < 0.05) or sham-
surgery animals (p < 0.05). By day 29, tumor-bearing animals subjected to MF1+DC101 
treatment also displayed significant deficits compared with sham-surgery animals (p < 
0.01). MF1+DC101-treated tumor-bearing animals did not show worse behavioral 
deficits in comparison with their untreated tumor controls at comparable time points 
before day 27. 
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Figure 6.1:  Retarded onset of significant behavioral deficits in U87 tumor-bearing mice 
after MF1 and DC101 treatment.  
Animals’ behaviors were measured by the rearing (forelimb-use asymmetry) test. * p < 
0.05 compared to sham controls, # p < 0.05 compared to untreated tumor controls, at 
corresponding time points. 
6.4.2 Reduced U87 glioma growth under treatment with MF1 and DC101 
The mice were sacrificed after they had lost over 20% of their body weight, and 
all surviving animals were sacrificed at day 29. Tumor size was measured on H&E-
stained slices. Fig. 6.2 A and B show representative slices from the U87 tumor control 
group (Fig. 6.2 A) and the MF1+DC101-treated U87 tumor group (Fig. 6.2 B), 
respectively. The tumor size of the tumor control group was significantly larger than that 
of its MF1+DC101-treated counterpart (Fig. 6.2 C, p < 0.01).  
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6.4.3 Increased tumor necrosis and apoptosis and reduced tumor cell proliferation 
after treatment with MF1 and DC101 
Treatment-related pathological changes in tumor tissues were identified with 
H&E staining. A marked decrease in cellularity and patches of necrosis with disperse 
extravascular hemorrhage were observed in MF1+DC101-treated U87 tumors (Fig. 6.2 
E), compared with U87 tumor controls (Fig. 6.2 D).  
The TUNEL assay revealed that MF1+DC101-treated U87 tumor cells (Fig. 6.2 
G) had a significantly higher rate of apoptosis (Fig. 6.2 H, p < 0.01) than untreated U87 
tumor cells (Fig. 6.2 F).  
A significant decrease in tumor cell proliferation, as measured by the number of 
Ki67 positive cells (Fig. 6.2 K, p < 0.01) was seen in MF1+DC101-treated U87 tumors 
(Fig. 6.2 J) compared with their untreated counterparts (Fig. 6.2 I). 
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Figure 6.2:  Reduced U87 tumor growth after MF1 and DC101 treatment.  
A and B, Representative H&E-stained U87 tumor slices obtained from mice without 
treatment sacrificed sequentially between day 23 and day 29 (A) and from those treated 
with MF1+DC101 sacrificed at day 29 (B) after tumor implantation. C, The mean tumor 
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size decreased significantly after MF1+DC101 treatment. D and E, magnified H&E-
stained images of the U87 tumors treated with (E) or without (D) MF1+DC101. 
Extravascular hemorrhage and patchy necrosis are present in MF1+DC101-treated U87 
tumors (E). F and G, TUNEL-stained images of the U87 tumors treated with (G) or 
without (F) MF1+DC101. H, MF1+DC101 treatment resulted in a significant increase in 
tumor cell apoptosis, as measured by the density of the TUNEL-positive cells (dark 
brown). I and J, Ki67-stained images of the U87 tumors treated with (J) or without (I) 
MF1+DC101. K, MF1+DC101 treatment resulted in a significant decrease in tumor cell 
proliferation, as measured by the density of the Ki67-positive cells. * p < 0.05 compared 
to untreated U87 tumor controls in C, H and K. Scale bars, 1 mm in A, 100 µm in D and 
I, 200 µm in F. 
The vessel density and the volume of the regions containing abnormally-high-
density neovascularization were measured on fluorescence images obtained after 
administration of the fluorescent dextran. The volume of the regions containing aberrant 
neovascularization was slightly larger than the corresponding tumor volume (data not 
shown). The volume of the regions containing aberrant neovascularization was 
significantly reduced following MF1+DC101 treatment in parallel with the volume of the 
tumor. However, the vascular density inside the MF1+DC101 treated tumors was not 
significantly different from that of untreated control tumors (data not shown). 
6.5 DISCUSSION 
6.5.1 Importance of functional assessment in preclinical research of brain tumor 
therapy 
In earlier research, the rationale for the safety of antiangiogenic agents lies in 
limited angiogenesis in the adult brain. Thus, therapies that target specific receptors, 
which are upregulated on proliferating endothelium, could potentially avoid widespread 
toxicity in the patient (Scappaticci, 2002). However, brain insults from tumor expansion 
and surgery may render the brain more vulnerable. There is evidence that inhibition of 
endogenous VEGF impedes revascularization and astroglial proliferation during the 
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repair of brain injury (Krum and Khaibullina, 2003). Therefore, functional evaluation is 
indispensable in brain tumor research and may lead to better decision-making when 
weighing the benefits and risks of a specific cancer treatment.  
6.5.2 Behavioral changes in mouse models of brain tumors 
Mouse tumor models are particularly useful because in contrast to rats, there are 
many genetically engineered mice, and various antibodies have been produced targeting 
mouse antigens. The present study showed, for the first time, behavioral changes in 
mouse models of brain tumors and introduced functional assessment into brain tumor 
treatment evaluation using mouse models. The rearing test primarily assesses forelimb 
motor asymmetry by producing quantitative scores, and has been shown to be sensitive 
and effective in various CNS lesion models in mice (Baskin et al., 2003; Starkey et al., 
2005; Wells et al., 2005). There were no changes in the general activity of the tumor-
implanted animals whose test results were collected. The behavioral deficits observed are 
mainly attributed to dysfunction or destruction of normal brain tissue in the SMC and 
underlying striatum due to tumor compression and invasion, whereas generalized 
increased intracerebral pressure (ICP) alone may not play an essential role because it 
should have produced bilateral deficits rather than asymmetries. 
Significant behavioral asymmetry was found in the late tumor-bearing stage. Our 
results are consistent with previous reports by Whittle and Marston and our investigations 
in rat glioma models (Whittle and Marston, 1997; Yang et al., 2007b).  
6.5.3 Rationale for using antiangiogenic therapy targeting both VEGFR-1 and -2 to 
treat gliomas 
VEGF secreted by glioma cells is a pivotal mediator of tumor neoangiogenesis 
(Plate et al., 1992; Plate et al., 1993). Accumulating evidence indicates the central role of 
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the VEGF/VEGF-2 signal transduction system for tumor angiogenesis and tumor growth 
(Millauer et al., 1994; Millauer et al., 1996). Systemic treatment with a monoclonal 
antibody against VEGFR-2 (DC101) inhibits tumor angiogenesis and growth of several 
mouse and human tumors, including gliomas (Prewett et al., 1999; Kunkel et al., 2001; 
Davis et al., 2004). A newly recognized role of VEGFR-1 in mobilization and functional 
incorporation of bone-marrow-derived cells into rapidly expanding tumor vasculature 
makes VEGFR-1 an intriguing target for antiangiogenesis therapy (Carmeliet et al., 2001; 
Hattori et al., 2002; Rafii et al., 2002). Inhibition of VEGFR-1 with a monoclonal 
antibody (MF1) attenuates the growth and vascularization of VEGF-transduced rat C6 
gliomas implanted in nude mice (Luttun et al., 2002). Recent data demonstrate enhanced 
tumor suppression by combination of the two antibodies targeting both VEGFR-1 (MF1) 
and VEGFR-2 (DC101) in intradermally inoculated mice with either B6RV2 lymphoma 
or Lewis lung carcinoma cells, compared with the effects of either single neutralizing 
antibody (Lyden et al., 2001). All these previous findings warrant further exploitation of 
combined antibodies against both VEGFR-1 and VEGFR-2 in glioma management.  
The two neutralizing antibodies MF1 and DC101 were developed specifically for 
mice, and an in vivo brain cancer model with a human origin glioma cell line may better 
recapitulate the clinical situation. We employed the orthotopic nude mouse model of 
human U87 glioma to investigate the effect of the combination antibody therapy for 
malignant gliomas. The current study is the first, to our knowledge, to employ this novel 
antiangiogenic regimen to treat gliomas. 
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6.5.4 Functional effects of the novel antiangiogenic treatment targeting both 
VEGFR-1 and -2 on the tumor-bearing brain  
It is important to use a model that, at some time points, yields very minor deficits, 
or no deficits, in untreated animals so that treatments that exaggerate dysfunction can be 
readily detected. In this study, we demonstrate that antiangiogenic treatment with MF1 
and DC101 delayed the onset of significant behavioral deficits by inhibiting tumor 
growth. Our results bear out the presumption that brain tumor patients may benefit, with 
an enhanced quality of life, from a long-term cytostatic therapy like the antiangiogenic 
therapy, if it can continuously limit tumor progression within the dormant stages. 
However, because angiogenesis may play a role in functional plasticity during tumor 
growth (Yang et al., 2007b), as it does in cerebral ischemia (Wei et al., 2005a), and 
inhibition of angiogenesis was shown to impede brain repair in a rat model of stab-wound 
injury (Krum and Khaibullina, 2003), the behavioral deficits that occurred in the MF1 
and DC101-treated glioma mice may be influenced overlappingly by tumor-related injury 
and inhibition of neuroplasticity by antiangiogenesis. Recently we found that certain anti-
cancer therapies had an adverse effect on functional outcome in a rat model in which 
mass-related events were fixed (Yang et al., 2006b; Yang et al., 2006a). To address 
whether antiangiogenic therapy can interfere with the tumor-induced neuroplastic 
mechanisms which help keep the tumor “dormant” by not exhibiting noticeable 
functional deficits, we propose to compare behavioral performance of animals bearing a 
similar size tumor with or without antiangiogenic therapy. Furthermore, tumor therapy 
can be screened and optimized by analyzing and comparing behavioral performance of 
animals with similar-size tumor but receiving different kinds of anti-cancer treatments, 
and eventually, treatments that have comparable efficacy in limiting tumor progression 
but better efficacy in permitting neuroplasticity to take place optimally will be favored. 
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6.5.5 Suppression of glioma growth by the novel antiangiogenic treatment targeting 
both VEGFR-1 and -2 
Our results demonstrate that systemic administration of combined MF1 and 
DC101 leads to a 69% reduction in mean tumor volume, a 66% decrease of proliferative 
activity and a 1.9-fold-increased apoptotic rate, compared with untreated tumor control. 
Based on a previous report that IgG may have a significant effect only when treatment is 
initiated immediately after tumor implantation, instead of against established tumors 
(Kunkel et al., 2001), we simply used untreated tumors as controls. Previous studies 
showed evidence of decreased tumor vascular density following continuous MF1, 
DC101, or MF1 + DC101 treatment (Kunkel et al., 2001). However, in this study, the 
vascular density inside the tumors was not significantly altered by MF1 + DC101 
treatment, when it was examined two weeks after cessation of MF1 + DC101 
administration. Furthermore, it was reported that withdrawal of DC101 treatment resulted 
in regrowth of tumors with similar kinetics to that of tumor controls in various tumor 
models (Prewett et al., 1999). Taken together, these results suggest that withdrawal of 
antiangiogenic therapy leads to vascular regrowth which provides a basis for progression 
of tumor growth. Therefore, it may be necessary to deliver antiangiogenic agents in 
sufficient quantities over a sustained period of time for the management of malignant 
gliomas. We sacrificed animals while they were still behaviorally testable to examine 
tumor size and its relationship to functional outcome. Our gross observations on survival 
rate indicate that systemic administration of combined MF1 and DC101 can prolong the 
survival time of glioma-bearing animals.  
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6.5.6 Summary 
We demonstrated the capability of using behavioral measurement to assess brain 
tumor progression in mice. Evaluating functional outcome after anti-cancer treatment in 
mouse glioma models may be a valuable adjunct to brain imaging and survival analysis in 
the development of efficient screening methods for preclinical research. Future research 
should focus not only on maximizing the anti-cancer benefits of brain tumor treatments 
but also on limiting potential adverse effects on neuroplasticity and recovery of function. 
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Chapter 7:  Systemic Administration of BCNU Suppresses Glioma 
Growth and Inhibits the Onset of Glioma-induced Sensorimotor Deficits   
7.1 ABSTRACT 
This study investigated the behavioral responses to systemic administration of a 
classic chemotherapy drug － 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in 9L 
glioma-bearing rats. MRI was used to dynamically evaluate tumor response to therapy. 
We found that a single bolus of BCNU dramatically inhibited tumor growth and the onset 
of glioma-induced somatosensory deficit. One rat exhibited delayed placing deficit after 
the use of BCNU, suggesting chemo-induced central neurotoxicity. Assessment of 
learning and memory function is warranted to further investigate BCNU-associated 
neurotoxicity.  
7.2 INTRODUCTION 
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) kills tumor cells via its 
carbamoylating cytotoxicity, which irreversibly inhibits glutathione reductase with 
resultant accumulation of oxidized form of glutathione causing oxidative stress (Yang et 
al., 2005). Furthermore, BCNU significantly delays the tumor doubling time contributing 
to the delay of tumor repopulation (Ross et al., 1998). Experimental in vitro and in vivo 
studies have shown that BCNU is an effective treatment for malignant gliomas 
(Rosenblum et al., 1975; Rosenblum et al., 1976; Rosenblum et al., 1977; Rosenblum et 
al., 1980). The efficacy of BCNU and/or radiotherapy in the treatment of glioma patients 
who were operated on has been demonstrated in clinical trials (Walker et al., 1978). 
Currently, BCNU is the FDA approved mainstay in clinical chemotherapy for malignant 
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gliomas. However, the clinical outcome of patients treated solely with BCNU is not as 
efficacious as would be predicted by the responses observed in the experimental tumor 
model (Kornblith and Walker, 1988).  
Fatal central neurotoxicity that commonly presents as leucoencephalopathy has 
been reported in clinical observations complicating the treatment of malignant gliomas 
with BCNU, especially through the intra-arterial and the intracarotid routes (Foo et al., 
1986; Mahaley et al., 1986; Rosenblum et al., 1989). Previous study on neurotoxicity of 
chemotherapeutic agents after blood-brain barrier (BBB) modification suggests that the 
lack of neurotoxicity associated with the usual administration of most chemotherapeutic 
agents likely stems from limited entry of drug into the brain through an intact BBB 
(Neuwelt et al., 1983b).  
9L tumor is induced by N-methylnitrosourea and classified as a gliosarcoma. The 
9L rat brain tumor has been developed as both in vivo and in vitro models and used for 
more than forty years to investigate a variety of potential therapeutic agents, 
combinations, schedules, and approaches that might be applicable to the management of 
high-grade malignant brain tumors (Kimler, 1994). Animal survival, clonogenic cell 
survival, and tumor growth delay traditionally provide means to measure the 
effectiveness of treatment modalities in this tumor model (Weizsaecker et al., 1981).  
The goal of the present study was to investigate the behavioral responses to 
systemic administration of BCNU using the classic 9L rat brain tumor model. MRI was 
used for dynamic assessment of tumor response to therapy. 
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7.3 MATERIALS AND METHODS 
7.3.1 Animals 
A total of 16 adult male Fischer rats (Charles River Breeding, Wilmington, MA) 
weighing 180-250 g were used in this study. 
7.3.2 9L gliosarcoma cell culture and 9L cell implantation in Fischer rats 
All 16 rats were subjected to intracerebral implantation of 9L glioma cells. Please 
see the related method in Chapter 5. 
7.3.3 BCNU treatment regimen 
Five days after the tumor implantation, 8 tumor-bearing rats received a single 
dose of 26.6 mg/kg BCNU therapy through i.p. injection. The BCNU dose was 
equivalent to double an LD10 dose, based on previous literature (Ross et al., 1998; 
Schepkin et al., 2005; Schepkin et al., 2006).  
7.3.4 Behavioral testing 
Behavioral tests, including forelimb-use asymmetry, somatosensory asymmetry, 
and vibrissae-evoked forelimb placing tests, were carried out before and after BCNU 
treatment. Please refer to the method details in Chapter 2. 
7.3.5 MRI measurement 
Please see Chapter 5 for details. 
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7.3.6 Statistical analysis 
One-way ANOVA was used to determine differences in both functional 
performance and tumor growth between the tumor-bearing animals with or without 
BCNU treatment at each time point. Repeated-measures ANOVA was used to evaluate 
the within-subject effects before vs. after BCNU treatment.  
7.4 RESULTS 
Tumor-bearing animals without BCNU treatment started to die on day 14 after 
tumor implantation. One BCNU-treated rat died on the day of BCNU injection, and 
another died 10 days after BCNU injection, while the remaining BCNU-treated tumor-
bearing rats were still alive on day 35 after tumor implantation. Nontreatment tumor-
bearing animals displayed significant somatosensory asymmetry on day 14, while the 
average performance in forelimb-use did not change after tumor implantation. One 
untreated tumor-bearing rat showed both same-side and cross-midline placing deficits on 
its contralateral side 14 days following tumor implantation. One-way ANOVA revealed 
that tumor-burdened animals with BCNU treatment showed significantly less behavioral 
deficits than their untreated counterparts in the somatosensory asymmetry test on day 14 
following tumor implantation (p < 0.05, Fig. 7.1). Repeated-measures ANOVA showed 
no significant within-subject effects before vs. after BCNU treatment in all three 
behavioral tests. However, one rat from the tumor+BCNU group displayed substantial 
cross-midline placing deficit on day 27, and the deficit persisted on day 35 after tumor 
implantation.  
MRI measurement demonstrated that the tumors were significantly smaller in the 
BCNU-treated tumor group than those in the tumor control group, on days 12 (p < 0.05) 
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and 16 (p < 0.01) after tumor implantation (Fig. 7.2). The tumor size was still very small 
in the BCNU group 35 days post tumor implantation with an average only 0.10 mm3.  
 
 
Figure 7.1:  Systemic BCNU treatment inhibits the onset of glioma-induced 
somatosensory deficit.  
The somatosensory asymmetry score in the tumor+BCNU group was significantly lower 

























Figure 7.2:  Systemic BCNU treatment inhibits tumor growth.  
The tumor volume in the tumor+BCNU group was significantly smaller than that in the 
tumor control group measured on days 12 and 16 after tumor implantation. * p < 0.05. 
7.5 DISCUSSION 
Consistent with our previous study (Yang et al., 2007b), nontreatment glioma-
bearing animals exhibited significant somatosensory deficit at the late stage of tumor 
growth, and a minority of them showed a placing deficit, while their average performance 
in forelimb-use was similar to that of normal ones. 
Our results demonstrated that systemic administration of BCNU suppressed 
glioma growth and prolonged the survival of the glioma-bearing rats. These results are 
consistent with previous studies on the effectiveness of BCNU in treating gliomas 
(Rosenblum et al., 1975; Rosenblum et al., 1976; Rosenblum et al., 1977; Rosenblum et 





























significant increase in life span in the 9L gliosarcoma-burdened rats (Rosenblum et al., 
1976).  
Concurrent with the inhibition of tumor growth, BCNU inhibited the onset of 
glioma-induced somatosensory asymmetry. We have previously proved the highly 
significant correlation between magnitude of somatosensory asymmetry and tumor 
volume measured by MRI (Yang et al., 2007b). The somatosensory asymmetry test can 
detect tumor progression dynamically, non-invasively, and inexpensively, although not as 
accurately and sensitively as MRI. In addition to measuring tumor volume, proton and 
sodium MRI can reveal early changes in tumor sodium content and cellularity and 
therefore can be used as a biomarker to assess earliest response to cancer therapy 
(Schepkin et al., 2005; Schepkin et al., 2006).  
Although the average performance in both forelimb-use and somatosensory 
asymmetry tests did not alter after BCNU treatment, there really were some signs of 
BCNU-induced neurotoxicity. One animal died on the same day of BCNU injection; 
another died ten days after; and still another one showed persistent placing deficit three 
weeks after BCNU treatment. Previous clinical observation documented that the BCNU-
induced neurotoxicity was usually delayed, commencing several weeks following BCNU 
treatment (Mahaley et al., 1986). In this study, BCNU-treated animals were allowed to 
live for 5 weeks. Long-term follow-up study is warranted to investigate possible delayed 
placing deficit. Clinical pathological and neuroimaging studies demonstrated that the 
central neurotoxicity following BCNU chemotherapy, presenting as massive coagulative 
necrosis involving primarily though not exclusively the white matter, was mediated by 
vascular injury and direct neural damage (Foo et al., 1986; Mahaley et al., 1986; 
Rosenblum et al., 1989). A study in rats showed changes in BBB permeability and 
neurotoxicity after intracarotid BCNU administration, in which ipsilateral subcortical 
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structures such as the hypothalamus, amygdala, internal capsule, and caudate putamen 
had the highest incidence of neurotoxicity, closely related to the histopathological 
damage seen in human BCNU leucoencephalopathy (Nagahiro et al., 1991). The lack of 
change in forelimb-use and somatosensory performance after BCNU therapy may be 
because both sides of the brain were affected by systemic BCNU administration and the 
two asymmetry tests are not able to detect bilateral deficits. Furthermore, the 
sensorimotor asymmetry tests are usually used to examine damage to the sensorimotor 
cortex and the striatum (Schallert et al., 2000; Schallert et al., 2002; Schallert and 
Woodlee, 2005), and they may not be sensitive enough to detect the deficit produced by 
the BCNU-affected subcortical brain structures. Our previous study demonstrated that 
local fluorouracil chemotherapy exaggerated brain tissue loss and functional impairments 
after focal cortical compression, through inducing elevated necrosis and apoptosis in the 
compressed brain (Yang et al., 2006a). Local infusion of the chemotherapeutic agents 
into the brain areas where functional tests can detect damage may increase the positive-
finding rate of chemo-induced central neurotoxicity. Nitrosourea-based chemotherapy 
can cause dementia (Vigliani et al., 1999; Plotkin and Wen, 2003; Aarsen et al., 2006). 
Hippocampus and amygdala are two pivotal brain structures associated with learning and 
memory and are also vulnerable to damage by BCNU therapy. Therefore, behavioral 
testing for learning and memory function is warranted to further investigate BCNU-
induced neurotoxicity. 
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Chapter 8:  Photofrin-mediated Photodynamic Therapy Induces 
Behavioral Deficits and Attempts at Using a Neurorestorative Agent for 
Functional Recovery 
8.1 ABSTRACT 
This study investigated the behavioral deficits following high-dose photodynamic 
therapy (PDT) applied to normal rat brain and the functional outcome of PDT-treated rats 
after neurorestorative treatment by atorvastatin. Photofrin™ at 2 mg/kg was injected 
intraperitoneally 24 hours before laser treatment as photosensitizer. The dose of laser 
energy was 280 J/cm2. Atorvastatin at 3 mg/kg was administered orally every day for 14 
days starting 24 hours after laser treatment. We found that PDT induced significant 
behavioral deficits, however, atorvastatin failed to promote functional recovery after 
PDT.  
8.2 INTRODUCTION 
Experimental photodynamic therapy (PDT) of cancer has a 100 year-history, and 
for more than 25 years, PDT has been established in the clinical environment as a useful 
adjuvant to standard cancer treatments (Stylli and Kaye, 2006a, b). PDT involves 
exposure to tissue-penetrating laser light following systemic administration of a 
photosensitizing drug, such as Photofrin, which is absorbed and accumulated by cancer 
cells with some selectivity. When exposed to light, the photosensitizing drug produces 
toxic oxygen species and kills the cancer cells (Goodell and Muller, 2001; Huang, 2005; 
Stylli and Kaye, 2006a, b). Clinical trials are currently in progress evaluating PDT as a 
treatment for a number of cancers including cancer of the prostate, oesophagus, head and 
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neck, and brain tumors. In February 2006, PDT has been approved by the national 
institute for health and clinical excellence (NICE) to treat some types of skin cancer.  
Since 1980, over five hundred glioma patients have been treated globally with 
PDT. An intra-operative PDT procedure has been introduced to clinic, in which 
photoillumination is carried out to the tumor cavity produced by surgical resection, 
(Perria et al., 1980; Muller and Wilson, 1990). Several clinical studies showed that 
adjuvant PDT following surgical resection of the tumor significantly prolonged the 
median survival of patients with newly diagnosed or recurrent gliomas (Muller and 
Wilson, 1995, 1996; Stylli et al., 2005). Treatment responses appear to be related to 
adequate light delivery to the tumor (Muller and Wilson, 1990, 1996). Experimental 
studies of glioma response to PDT showed that increasing optical energy doses led to 
increased volume of tumor necrosis (Chopp et al., 1996a; Chopp et al., 1996b). However 
increasing the light dose delivered to the tumor increases the risks of inducing a 
permanent neurological deficit (Krishnamurthy et al., 2000). 
The currently available photosensitizers have limited selectivity with regard to 
cancer cells and their retention in the normal tissue is unavoidable. Although Photofrin is 
retained in the tumor tissue to a higher degree than the normal brain tissue, the normal 
tissue is more sensitive to PDT than the tumor under identical treatment parameters 
(Dereski et al., 1991; Chopp et al., 1996a). 
Increased tumor elimination requires an increase in PDT intensity. However, 
increased PDT intensity leads to increased damage to normal surrounding tissue and 
aggravated neurological deficits. The concern on functional impairment sets the dose 
limit of PDT in the clinic. Current PDT doses are inadequate for complete elimination of 
the established brain tumor. The remaining tumor cells give rise to recurrent tumors. 
Therefore, high-dose PDT is needed to treat gliomas, and concurrently, a neurorestorative 
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strategy is desperately needed to promote functional recovery after the aggressive anti-
cancer treatment.  
Atorvastatin, with the brand name Lipitor, is a drug clinically used for the 
treatment of high cholesterol and triglyceride levels, and its long-term safety has been 
proved (Newman et al., 2006). Atorvastatin has recently been found to have 
neurorestorative effects, independent of its antilipid effects. Atorvastatin can improve 
functional outcome after stroke (Chen et al., 2003a; Chen et al., 2005), intracerebral 
hemorrhage (Seyfried et al., 2004), and traumatic brain injury (Lu et al., 2004c; Lu et al., 
2004b; Lu et al., 2004d; Lu et al., 2004a).  
The objective of this study was to investigate the behavioral deficits following 
high-dose PDT applied to normal rat brain and the functional outcome of PDT-treated 
rats after administration of atorvastatin.  
8.3 MATERIALS AND METHODS 
8.3.1 Animals  
A total of 32 adult male Fischer rats were used. 
8.3.2 Experimental model 
Light delivery: A semiconductor diode laser (University Health Network, 
Toronto, Canada) provided the light (635 ± 5 nm wavelength) for the PDT treatment. The 
light was coupled into a 200 µm diameter optical fiber with a distal microlens (PDT, 
Santa Barbara, CA, USA) for a 7 mm diameter, uniform spot for superficial irradiation. 
The power at the distal end of the fiber was adjusted to 100 mW and was measured 
before and after each treatment using a power meter (Photodyne, Westlake Village, CA, 
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USA) with a 1-inch integrating sphere detector head. The irradiation power was shown to 
be stable in all of the experiments. 
PDT treatment: Photofrin™ (QuadraLogic Technologies, Vancouver, BC, 
Canada) was dissolved in 5% dextrose solution. Consistent with the clinical dose of 
Photofrin™ (Muller and Wilson, 1996), 2 mg/kg Photofrin™ was administered i.p. to 18 
Fischer rats. Twenty-four hours after Photofrin™ administration, these animals were 
treated with laser. The surgery procedure was performed as described previously (Jiang et 
al., 1997; Jiang et al., 1998; Jiang et al., 2004). The rats were anesthetized by i.p. 
injections of ketamine (80 mg/kg) and xylazine (13 mg/kg). After the animals were fixed 
in a stereotaxic device, a 9-10 mm incision was carried directly down the midline, and the 
scalp was retracted to expose the cranium. Using a dental drill, a 5 x 5-mm-square 
craniectomy was made over the sensorimotor cortex. Laser light was delivered through 
the craniectomy. The optical dose employed in this study was 280 J/cm2. The 
craniectomy was then covered with a piece of polyvinyl chloride glued to the surrounding 
intact bone and the incision was closed with 4-0 silk sutures. Six rats served as surgery 
controls, having scalp incision and skull removal, but without Photofrin™ administration 
and laser treatment.  
Atorvastatin administration: Eighteen PDT-treated rats were equally divided into 
2 groups based on their behavioral performance 24 hours after laser treatment. Nine of 
them received a continued daily oral administration of 3 mg/kg atorvastatin for 14 days 
starting 24 hours after laser treatment. Atorvastatin at this oral dose was shown to 
promote functional recovery after stroke in rats (Chen et al., 2003a). The other nine 
animals served as PDT-treated controls.  
Histological studies were carried out on 8 additional animals that underwent PDT 
treatment, but these animals did not receive atorvastatin. Three of them were sacrificed 
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on day 3 and the other 5 were sacrificed on day 7 after laser treatment to examine for the 
PDT-induced lesion.  
8.3.3 Behavioral testing 
Behavioral tests, including forelimb-use asymmetry, somatosensory asymmetry, 
and vibrissae-evoked forelimb placing tests, were carried out before and after surgical 
procedures. Please refer to the method details in Chapter 2. 
8.3.4 Histological assessment 
Tissue preparation: Eight PDT-treated animals were sacrificed on days 3 and 7, 
respectively, after laser treatment, and the other 24 animals that underwent behavioral 
testing repeatedly were sacrificed two weeks after surgery. Under anesthesia, they were 
perfused and fixed with 4% paraformaldehyde. Brains were removed, processed, 
embedded in paraffin, and cut into seven 2-mm-thick coronal blocks.  
Pathological examination: Six-µm-thick coronal sections containing the lesion 
were stained with hematoxylin and eosin (H&E) for microscopic examination. 
8.3.5 Statistical analysis 
Raw scores from the four behavioral tests, including forelimb-use asymmetry, 
magnitude of somatosensory asymmetry, same-side placing and cross-midline placing, 
were combined to produce a composite score for each animal at each time point, as 
described in Chapter 5. Repeated-measures ANOVA was applied to analyze behavioral 
data across time. One-way ANOVA was used to examine behavioral differences among 
the three groups at each time point. Data are presented as mean ± standard error. 
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8.4 RESULTS 
Behavioral data are shown in Figure 8.1. Repeated-measures ANOVA showed 
that there were significant time effect (F(6,126) = 26.559; p < 0.001), significant group 
effect (F(2,21) = 10.914; p < 0.01), and significant time by group effect (F(12,126) = 
4.827; p < 0.001) among the three groups. Post-hoc analyses revealed significant 
differences between the PDT-only group and the surgery control group (p < 0.01), and 
between the PDT + atorvastatin group and the surgery control group (p < 0.01); however, 
the PDT + atorvastatin group and the PDT-only group were not significantly different. 
One-way ANOVA showed that there were significant differences among the three groups 
at day 2 (F(2,21) = 18.088; p < 0.001), day 5 (F(2,21) = 6.200; p < 0.01), day 7 (F(2,21) 
= 4.318; p < 0.05), and day 9 (F(2,21) = 6.462; p < 0.01). Post-hoc analyses revealed that 
the PDT-only rats displayed significantly more behavioral deficits than the surgery 
controls at day 2 (p < 0.001), day 5 (p < 0.01), day 7 (p < 0.05), and day 9 (p < 0.01), and 
that the PDT-treated rats receiving atorvastatin exhibited significantly more behavioral 
deficits than the surgery controls at day 2 (p < 0.001), day 5 (p < 0.05), and day 9 (p < 
0.05); however, the PDT + atorvastatin group did not significantly differ from the PDT-
only group at any time point.  
H&E staining revealed substantial necrosis, patchy hemorrhage, and vacuolization 
in the PDT lesion area 3 days after PDT (Fig. 8.2 A). Hemorrhage was absorbed 7 days 
after PDT (Fig. 8.2 B). The lesion shrank and became less manifest 14 days after PDT 

























PDT+Atorvastatin (n=9) PDT only (n=9) surgery control (n=6)
 
Figure 8.1:  Behavioral response to high-dose PDT and functional outcome after 
atorvastatin administration to PDT-treated rats.  
Composite behavioral results showed that PDT induced significant behavioral deficits, 
however, atorvastatin failed to promote functional recovery after PDT.  
 
 
Figure 8.2:  Histological images of PDT-induced brain damage.  
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H&E staining images (100 times magnification) collected from brains 3 days (A), 7 days 
(B), and 14 days (C), respectively, after PDT. PDT induced significant damage to the 
normal brain. Bar = 100 µm. 
8.5 DISCUSSION 
This study investigated the behavioral responses under PDT with a combination 
of the clinically relevant dose of 2 mg/kg Photofrin and a high optical dose of 280 J/cm2 
laser light. PDT-treated animals exhibited significant behavioral deficits. Concurrently, 
histological examination demonstrated substantial brain damage associated with PDT. 
Previous studies showed that normal brain is extremely vulnerable to PDT damage (Chen 
et al., 1996). PDT generated necrosis in normal brain was found to be a function of 
incident optical energy dose, with lesions histologically detectable at a dose as low as 3 
J/cm2 (Dereski et al., 1991; Chopp et al., 1996a; Chopp et al., 1996b).  
We did not find any neurorestorative effect of atorvastatin after PDT. Atorvastatin 
has been shown to promote functional recovery after stroke (Chen et al., 2003a; Chen et 
al., 2005), intracerebral hemorrhage (Seyfried et al., 2004), and traumatic brain injury (Lu 
et al., 2004c; Lu et al., 2004b; Lu et al., 2004d; Lu et al., 2004a). Increased production of 
vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor 
(BDNF) (Chen et al., 2005), induction of neurogenesis, angiogenesis, and synaptogenesis 
(Chen et al., 2003a; Lu et al., 2004c; Seyfried et al., 2004), and reduction of intravascular 
thrombosis (Lu et al., 2004b; Lu et al., 2004d) and hematoma (Lu et al., 2004a), all likely 
contribute to the neurorestorative effects of atorvastatin. In this study, there was a 
dramatic spontaneous functional recovery after PDT, which may have masked the 
neurorestorative effect of atorvastatin. Furthermore, no close assessment was done to 
investigate whether atorvastatin showed the same stimulatory effects on neuroplasticity in 
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the PDT model as in other models. There is a possibility that atorvastatin may have no 
neurorestorative effects after PDT-induced cortical damage.  
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Chapter 9:  General Discussion and Future Directions  
Together, this set of studies focus on a relatively neglected, but potentially crucial 
area of preclinical brain tumor research: functional assessment and neuroplasticity. 
Optimal treatment strategies should limit or reduce tumor growth without compromising 
the integrity of the brain. 
We characterized the behavioral responses of focal brain compression in a model 
of rapid displacement of brain tissue elicited by epidural implantation of a hemisphere-
shaped plastic bead (Yang et al., 2006c). The rapid brain compression induced mild 
behavioral deficits which depended on the location, magnitude and duration of the focal 
compression, and which resolved spontaneously even while the compression remained 
(Yang et al., 2006c). We then examined the impact of some cancer interventions on the 
compressed brain. Long-term administration of the NMDA receptor antagonist MK801 
did not change the recovery rate but caused a reinstatement of behavioral deficits after 
complete recovery from focal brain compression (Yang et al., 2006b). Local 
chemotherapy with fluorouracil exacerbated compression-induced functional deficits 
(Yang et al., 2006a). This controlled mass compression model does not have the growth 
and invasion properties of an actual tumor, but isolates the compression characteristics of 
a brain tumor, allowing investigation of the functional impact of anti-cancer treatments 
on the compressed brain, independent of their tumor-shrinking effects. The mild lesion 
pattern of this mass compression model makes it especially suitable to detect the adverse 
effects of anti-cancer treatments on functional integrity of the brain.   
Further histological assessment is warranted to investigate whether mass 
compression can change the ventricle size and how different magnitudes of mass 
compression would affect the ventricle size. Furthermore, future improvements may 
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include a controlled-rate compression device that is able to inflate and deflate slowly over 
weeks or months. Such an advance in the technique would more closely model the 
slower-growing property of many tumors. Because the inert mass cannot secrete 
chemicals and invade the surrounding brain tissue, the focus would be on manipulation of 
tumor mass so that compression and plasticity effects can be examined specifically. 
Future study would benefit from a controlled-rate focal compression model to test anti-
cancer drugs with similar tumor-shrinking effects, and to screen for the ones with reduced 
harm to the compressed brain and its plastic ability.  
We investigated the behavioral responses as the brain tumor progresses and found 
a late-onset pattern of the behavioral deficits (Yang et al., 2007b). Tumor size typically 
increases faster and faster toward the late stage of its growth. The time when behavioral 
deficits occur is the time of the steep incline of the tumor growth. Rapid growth of the 
tumor strongly attacks the surrounding normal brain tissue, and finally reveals itself. A 
brain tumor shares important characteristics of a slow-degenerative brain lesion, inducing 
neuroplasticity continuously. Previous study characterized the neurogenic response of the 
subventricular zone (SVZ) to the growth of malignant brain tumors in the striatum 
(Duntsch et al., 2005; Glass et al., 2005; Bexell et al., 2007). We demonstrated astrocytic 
activation, angiogenesis, and synaptogenesis in the peritumoral area, which are all 
reactive neuroplastic responses to lesions (Yang et al., 2007b) that may or may not 
involve the SVZ directly. We further investigated the impact of some anti-cancer 
treatments on the tumor-bearing brain. Antiangiogenic treatment with a combination of 
antibodies against both the VEGF receptors 1 and 2 delayed the onset of brain tumor-
induced behavioral deficits (Yang et al., 2007a). Systemic chemotherapy with BCNU 
inhibited the occurrence of behavioral deficits associated with tumor growth, but a 
minority of animals showed deficits possibly associated with delayed chemo-induced 
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neurotoxicity (Chapter 7). It is difficult to find the neurotoxicity and the adverse effects 
on neuroplasticity when the treatments are administered systemically in a tumor 
implantation model, because the tumor-slowing or shrinking effects can mask the adverse 
effects on the remaining brain function, unless the adverse effects are very severe and 
occur in the tumor-dormant stage before the tumor grows large. This tumor implantation 
model may not be sensitive enough to reveal suboptimal treatments, but it can well 
recapitulate the clinical situation, and can test the anti-cancer effects directly. Therefore, 
the advantage of this model is that it can show the integrative effects, and treatments can 
be compared and optimized. Use of both a tumor implantation model and a controlled-
rate non-tumor compression/deflation model may improve investigation of optimal 
treatments.  
Further behavioral assessment will be conducted in glioma-bearing rats using the 
water maze test because hippocampus is affected as well by the tumor in this model. 
Behavioral tests for bilateral functional assessment are needed because increased 
intracerebral pressure affects bilateral function, and the tumor can compress and invade 
the contralateral hemisphere. We will also use the water maze test to investigate whether 
systemic administration of BCNU to the glioma-bearing rat can induce learning and 
memory deficits, because BCNU can limit the tumor growth within a very small size, and 
BCNU has been reported to cause dementia (Vigliani et al., 1999; Plotkin and Wen, 
2003; Aarsen et al., 2006). Further experiments are warranted to investigate the temporal 
pattern of peri-tumoral reactive neuroplastic responses. It will be interesting to block 
some neuroplastic events, for examples, anti-VEGF, anti-BFGF, or block their receptors, 
and then compare the behavioral responses of animals bearing the tumors of similar size 
and location with or without treatment. This experiment is aimed at investigating whether 
the tumor-induced neuroplastic mechanisms contribute to behavioral compensation. 
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Because the treatments that block neuroplasticity may also slow tumor growth, MRI is 
needed to monitor the tumor size and location, and the comparison will be made between 
treated and non-treated tumors of similar size while not considering time. It also would 
be intriguing to investigate whether life styles, for example, exercise, can affect glioma 
growth. Exercise can reduce the risk of breast cancer (Bernstein et al., 2005; Hewitt et al., 
2005; Tehard et al., 2006), significantly improve the quality of life (QOL) outcomes and 
physiological capacity of breast cancer survivors (Hewitt et al., 2005), prolong their 
survival (Holmes et al., 2005), and is likely to prevent recurrence of breast cancer (Hann 
et al., 2005). Running alone or combined with caffeine guards against skin cancer in mice 
(Michna et al., 2006; Lu et al., 2007). Also, motor enrichment and exercise have been 
shown to promote neuroplasticity and to rescue brain tissue from progressive 
degeneration in animal models of Parkinson’s, Alzheimer’s and other brain diseases 
(Kleim et al., 2003; Woodlee and Schallert, 2006). 
Furthermore, we need to test one same anti-cancer therapy administered at the 
same dosage, by the same route, and under the same schedule, in the non-tumor 
compression model and the tumor implantation model, respectively, to bridge these two 
treatment screening systems. An example of an anti-cancer treatment that can interfere 
with functional recovery in the non-tumor compression model but can slow tumor growth 
and concurrently delay the onset of significant functional deficits in the tumor 
implantation model, may better demonstrate the necessity of utilizing both models to 
screen for treatments with improved anti-cancer effects and reduced adverse effects on 
functional integrity of the brain. 
We found that high-dose photodynamic therapy (PDT) induced significant 
behavioral deficits in normal rats (Chapter 8). We attempted to use a neurorestorative 
agent atorvastatin to promote the functional recovery after PDT, but failed (Chapter 8). 
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There was a marked spontaneous functional recovery after PDT, and atorvastatin did not 
accelerate the recovery (Chapter 8). The neural toxicity of many cancer therapies, such as 
local radiation (Kim et al., 2004), local chemotherapy (Yang et al., 2006a), as well as 
PDT (Chapter 8), can be revealed through direct administration to normal brain. The 
advantage of this model is simplicity. However, unlike the focal compression model, 
interruption of neuroplasticity cannot be investigated as easily in the normal brain. 
Future research will be focused on establishment of a model with long-lasting 
behavioral deficits, and examination of whether neurorestorative strategies can promote 
functional recovery after cancer therapies. Such models may include aspiration lesion or 
stab wound lesions, designed to mimick as closely as possible certain aspects of tumor 
resection surgery, and focal delivery of radiation to the normal brain. Neurorestorative 
strategies may include physical therapy, gene therapy, other neurorestorative agents such 
as erythropoietin and sildenafil, and cell therapy (Zhang et al., 2002; Zhang et al., 2005; 
Chen and Chopp, 2006; Chopp and Li, 2006; Liu et al., 2006; Mahmood et al., 2006; 
McFarlin et al., 2006; Seyfried et al., 2006; Zhang et al., 2006; Mahmood et al., 2007a; 
Mahmood et al., 2007b; Shen et al., 2007a; Shen et al., 2007b; Wang et al., 2007a). 
Functional promotion effects should be established initially in the nontumor animal 
undergoing cancer therapies. The effects of the neurorestorative strategies on tumor 
growth and regrowth should also be examined in the tumor-bearing animal with and 
without cancer therapies. Our preliminary data showed that atorvastatin did not promote 
glioma growth in nude mice. Additional studies should explore potential integrative 
effects of combinations of cancer therapy and neurorestorative therapy in glioma-bearing 
animals. Functional outcome and survival time both should be included as outcome 
measures.  
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Note that animals can functionally recover by themselves from the bead 
compression, even when the bead remains implanted permanently (Yang et al., 2006c), 
from the 5FU intracerebral injection (Yang et al., 2006a), and from the photodynamic 
therapy (Chapter 8). This phenomenon occurs in other lesion types as well, such as stroke 
(Zhang et al., 2002; Zhang et al., 2005), and traumatic brain injury (Lu et al., 2004c; Lu 
et al., 2004d; Lu et al., 2005). The spontaneous functional recovery can be accounted for 
by the compensatory reorganization of the contiguous and remote brain areas (Weiller et 
al., 1992; Seitz et al., 1995; Nudo et al., 1996; Rossini et al., 1998; Cramer et al., 2000; 
Pineiro et al., 2001), and by the neuroplastic mechanisms, such as neurogenesis, 
angiogenesis, and synaptogenesis, to self-repair the brain damage to some extent 
(Gomez-Pinilla et al., 1992; Cramer and Chopp, 2000; Chao et al., 2002; Keyvani and 
Schallert, 2002; Mattson et al., 2002; Parent et al., 2002).  
In summary, the studies conducted for this dissertation started to fill a critical 
behavioral void in the early phases of translational brain tumor research. Longer term 
goals are to continue to develop models to facilitate functional assessment, to screen for 
optimal cancer treatment strategies with reduced harm to brain function, and to search for 
novel neurorestorative strategies to promote functional outcome following standard brain 
tumor treatments, such as surgery, radiation and chemotherapy. An improved 
collaboration among scientists in the areas of behavioral neuroscience, experimental and 
clinical neuro-oncology, neurosurgery and neurology would be needed to find better 
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